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ABSTRACT
Percutaneous transluminal angioplasty (PTA) is a common endovascular procedure that
restores blood flow in peripheral vascular disease. Unfortunately, endovascular procedures
inherently cause injury to intimal layer. This exposing the medial layer and vascular smooth
muscle cells (VSMCs) to hemodynamic flow. The injury response induces dysfunctional VSMC
phenotypes, leading to thickening of the vessel wall known as intimal hyperplasia (IH). Eventually,
IH leads to restenosis, a common complication of PTA.
Most therapeutic strategies for IH are aimed at reducing VSMC migration and
proliferation. However, recent studies have shown healing of the VEC layer is crucial mitigating
factor in IH. We postulate that an optimal intervention could be achieved by employing both
therapeutic strategies simultaneously in a cell-type specific manner at the site of PTA-induced
injury. Gene therapy techniques provide an opportunity to accomplish this goal. Many IHassociated genetic targets have been successfully modulated to improve reendothelialization of
VECs and inhibit the proliferation of VSMCs. However, clinical success of vascular gene therapy
is limited due to the lack of a translational delivery vehicle.
Liposomes have been shown to be effective gene vectors with translational efficacy. The
addition of polyethylene glycol (PEG) to liposomes (PLP) can improve in vivo pharmacokinetics,
but reduces cellular uptake of liposomal cargo.

Ligand-modified liposomes provide an

opportunity to enhance transfection of neutral PLPs and target specific cell types for gene
delivery. Cell-penetrating peptides (CPPs) containing arginine-rich motifs have the ability to
enhance membrane translocation of their conjugated cargo. Cell-targeting peptides (CTP) can
also be used to decorate the liposome surface, providing cell-type specificity. In this in vitro proofv

of-concept study, we aim to develop a modified PLP comprised of neutral lipids and capable of
enhanced transfection and cell-type specific delivery to VSMCs and VECs, respectively.
Using a Ca2+-mediated ethanol injection technique, a novel method for the self-assembly
of CPP-modified PLPs with enhanced transfection, optimized siRNA loading efficiency, minimal
cytotoxicity, and cell-targeting capabilities was developed. These nanocarriers convey chemical
stability to siRNA in the presence of nuclease activity. This liposomal delivery system could
provide the foundation necessary to increase the bench-to-bedside success of systemically
administered vascular gene therapy.

vi

TABLE OF CONTENTS
CHAPTER 1: Introduction ........................................................................................................... 1
1.1 Overview ............................................................................................................................................................... 2
1.2

Introduction to Peripheral Arterial Disease ............................................................................................. 3

1.2.1 Anatomy of the Vessel Wall...................................................................................................................... 4
1.2.2 Pathogenesis of Atherosclerosis .............................................................................................................. 7
1.2.3 Treatment of Atherosclerotic Lesions ................................................................................................. 10
1.3 Restenosis – Vessel Response to Injury ....................................................................................................... 12
1.3.1 Intimal Hyperplasia in a Balloon Injury Model..................................................................................... 12
1.3.2 Timeline of IH-associated Restenosis after Balloon Injury .............................................................. 14
1.3.3 Novel Therapeutic Strategies to Prevent PTA-induced Restenosis .............................................. 16
1.4 Gene Therapy ..................................................................................................................................................... 18
1.4.1 Mechanism of RNA Interference ........................................................................................................... 19
1.4.2 siRNA Targets in the Treatment of Intimal Hyperplasia .................................................................. 20
1.5 Gene Delivery .................................................................................................................................................... 22
1.5.1 Introduction to Liposomes ...................................................................................................................... 24
1.6 Research Summary ............................................................................................................................................ 30
1.6.1 Specific Aims ............................................................................................................................................... 32
CHAPTER 2: The Scalable Assembly of Noncationic PEGylated Liposomes with
Octaarginine-potentiated siRNA Encapsulation ...................................................................... 33
2.1 Introduction ........................................................................................................................................................ 34
2.2 Materials and Methods ..................................................................................................................................... 36
2.2.1 PLP Assembly via Ethanol Injection Technique................................................................................... 36
2.2.2 CPP Modification via R8 Amphiphile Incorporation .......................................................................... 37
2.2.3 Liposome Characterization Studies ....................................................................................................... 39
2.2.4 Vascular Smooth Muscle Cell Culture .................................................................................................. 42
2.2.5 Cell Association Studies ........................................................................................................................... 42
2.2.6 Statistical Analysis ...................................................................................................................................... 42
2.3 Results .................................................................................................................................................................. 43
2.3.1 Incorporation of R8-PEG via Pre-insertion, Post-insertion, and Post- conjugation Resulted in
Significant siRNA Leakage and Reduced Total siRNA Retention. .............................................................. 43
2.3.2 Incorporation of STR-R8 via Pre-insertion Resulted in Significantly Enhanced siRNA
Encapsulation and Retention. ............................................................................................................................... 43
vii

2.3.3 Ca2+-mediated EtOH injection of R8-PLPs Resulted in Homogenous Liposome Samples
Between 50-60nm with Increased siRNA Retention and EE%. ................................................................... 46
2.3.4 Increasing Lipid:siRNA Enhanced R8-PLP EE% to ~100%. ............................................................... 46
2.3.5 Partial Heparin Displacement Indicated siRNA Complexation to R8-PLP Surface in Addition
to Internalized R8-PLP Entrapment.................................................................................................................... 49
2.3.6 R8-PLP Nanoparticles Sufficiently Protected Encapsulated and Complexed siRNA Against
RNase A Degradation. .......................................................................................................................................... 51
2.3.7 Slower Injection Rates During R8-PLP Assembly Resulted in Increased Sample Homogeneity
but Showed No Correlation to EE%. ................................................................................................................ 52
2.3.8 R8-PLP Nanoparticles Demonstrated Enhanced Cell Association in vitro. .................................. 52
2.4 Discussion............................................................................................................................................................ 56
CHAPTER 3: Improving the Efficacy of Liposomal-mediated Vascular Gene Therapy via
Lipid Surface Modifications ........................................................................................................ 63
3.1 Introduction ........................................................................................................................................................ 64
3.2 Materials and Methods ..................................................................................................................................... 66
3.2.1 Neutral and Cationic Liposome Assembly via EtOH Injection ....................................................... 66
3.2.2 Liposome Characterization Studies ....................................................................................................... 68
3.2.3 Vascular Smooth Muscle Cell Culture .................................................................................................. 69
3.2.4 Cytotoxicity Assays ................................................................................................................................... 70
3.2.5 Cell Association Experiments ................................................................................................................. 70
3.2.6 Liposome Transfection and Gene Expression Analysis .................................................................... 71
3.2.7 Statistical Analysis ...................................................................................................................................... 71
3.3 Results .................................................................................................................................................................. 72
3.3.1 EtOH Injection Assembly of PLPs, R8-PLPs, and CLPs Results in Nanoparticles with Similar
Physical Characteristics. ........................................................................................................................................ 72
3.3.2 R8 Modification of PLPs Increases Encapsulation Efficiency of siRNA in a Concentration
Dependent Manner. ............................................................................................................................................... 72
3.3.3 Non-cationic Liposomes Exhibited Significantly Less Cytotoxic Effects Compared to Cationic
Liposomes................................................................................................................................................................. 75
3.3.4 R8 Lipid Surface Modification Significantly Increases the Cell Association of PLPs. .................. 75
3.3.5 Transfection with R8-PLPs, Modified at 10mol% STR-R8, Resulted in Significant GAPDH
silencing, in a Manner Dependent on Lipid-to-siRNA Load Capacity........................................................ 75
3.4 Discussion............................................................................................................................................................ 81
CHAPTER 4: The Assembly of Ligand-modified PEGylated Liposomes for Cell-type
Selectivity in Vascular Cell Types .............................................................................................. 87
4.1 Introduction ........................................................................................................................................................ 88
viii

4.2 Materials and Methods ..................................................................................................................................... 90
4.2.1 PLP Assembly via Ethanol Injection Technique................................................................................... 90
4.2.2 CTP-PLP assembly via VAPG and REDV Amphiphile Incorporation ............................................ 91
4.2.3 Liposome Characterization Studies ....................................................................................................... 92
4.2.4 Vascular Cell Culture ................................................................................................................................ 93
4.2.5 Cell Association Experiments ................................................................................................................. 93
4.2.6 Statistical Analysis ...................................................................................................................................... 94
4.3 Results .................................................................................................................................................................. 94
4.3.1 The Incorporation of CTP Does Not Significantly Affect Size or Homogeneity of CTP-PLPs
Compared to PLP Controls. ................................................................................................................................ 94
4.3.2 The Incorporation of VAPG-PEG into PLP Base Formulations Results in Desired
Morphological Characteristics. ............................................................................................................................ 94
4.3.3 The Incorporation of VAPG-PEG into SMC-PLPs Increases Cell Association Above PLP
Controls in VSMC but Not VEC. ....................................................................................................................... 98
4.3.4 The Incorporation of VAPG-PEG into SMC-PLPs via Post-insertion Does Not Significantly
Increase Cell Association in SMCs Compared to PLP Controls. ............................................................... 98
4.3.5 The Incorporation of REDV-PEG into EC-PLPs Increases Cell Association Above PLP
Controls in VEC but Not VSMC at Early Exposure. ..................................................................................... 98
4.3.6 The Incorporation of REDV-PEG into EC-PLPs Does Not Significantly Increase Cell
Association Above PLP Controls at Later Time Points. ............................................................................ 102
4.4 Discussion......................................................................................................................................................... 102
CHAPTER 5: Conclusions and Future Directions .................................................................. 107
5.1 Study Conclusions and Future Directions ................................................................................................ 108
BIBLIOGRAPHY ....................................................................................................................... 113
VITA ........................................................................................................................................... 122

ix

LIST OF TABLES
TABLE 2.1: QUALITY BY DESIGN APPROACH WHICH PROVIDES ESTABLISHED CRITERIA, OR CQAS, REQUIRED
FOR EFFECTIVE SYSTEMIC ADMINISTRATION OF LIPOSOMAL DRUG DELIVERY SYSTEMS. ................................. 36
TABLE 2.2: BULK LIPID CONSTITUENTS THAT COMPRISE THE LIPOSOME FORMULATIONS USED IN THIS STUDY.37
TABLE 2.3: R8-PLP MODIFICATION CONDITIONS. THE SIRNA RETENTION AND FINAL EE% ARE LISTED AS A
RESULT OF R8-MODIFICATION. .............................................................................................................................. 44
TABLE 2.4: R8-PLP MODIFICATION CONDITIONS. SIZE, PDI, AND ZETA POTENTIAL ARE MEASURED BEFORE
AND AFTER R8-MODIFICATION. ............................................................................................................................. 45
TABLE 3.1: LIPOSOME CONSTITUENTS............................................................................................................................ 67
TABLE 3.2: LIPOSOME CHARACTERIZATION. ................................................................................................................ 73
TABLE 4.1: LIPOSOME FORMULATION CONSTITUENTS AND ASSOCIATED ACRONYMS.......................................... 91

x

LIST OF FIGURES
FIGURE 1.1: PROGRESSION OF ATHEROSCLEROTIC DEVELOPMENT. ........................................................................... 5
FIGURE 1.2: ANATOMY OF THE ARTERIAL VESSEL WALL. .............................................................................................. 6
FIGURE 1.3: ILLUSTRATION OF MAJOR CELLULAR EVENTS AND POSSIBLE CRITICAL OUTCOMES OF
ATHEROGENESIS. ......................................................................................................................................................... 9
FIGURE 1.4: SURGICAL BYPASS AND PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY REVASCULARIZATION
PROCEDURES ARE COMPARED................................................................................................................................. 11
FIGURE 1.5: DIAGRAM OF MAJOR EVENTS IN THE DEVELOPMENT OF IH-INDUCED RESTENOSIS IN RESPONSE TO
VASCULAR INJURY COMMONLY SEEN IN PTA PROCEDURES. ............................................................................. 13
FIGURE 1.6: STAGED DEVELOPMENT OF INTIMAL HYPERPLASIA DEVELOPMENT AFTER PTA-INDUCED INJURY.27
.................................................................................................................................................................................... 15
FIGURE 1.7: MECHANISM OF RNAI. ............................................................................................................................... 21
FIGURE 1.8: COMPARISON OF COMMONLY USED VIRAL AND NONVIRAL VECTORS. .............................................. 22
FIGURE 1.9: ADVANTAGES OF LIPOSOMES AS PHARMACEUTICAL NANOCARRIERS IN MEDICINE. ......................... 26
FIGURE 1.10: GRAPHICAL ILLUSTRATION SHOWING EXPONENTIAL GROWTH OF LIPOSOME-RELATED
PUBLICATIONS IN MEDICINE AS WELL AS THE USE OF COMPUTATIONAL MODELING IN DEVELOPING
LIPOSOMAL DRUGS. .................................................................................................................................................. 26
FIGURE 1.11: SCHEMATIC REPRESENTATION OF DIFFERENT CLASSIFICATIONS OF LDS CAPABLE OF
ENCAPSULATING HYDROPHILIC AND HYDROPHOBIC DRUGS. .......................................................................... 29
FIGURE 1.12: LISTING OF LIPID CLASSES USED IN DISSERTATION WITH ASSOCIATED NOMENCLATURE AND
STRUCTURE. ............................................................................................................................................................... 31
FIGURE 2.1: MALDI-TOF SPECTROSCOPY CONFIRMATION OF SUCCESSFUL “CLICK” REACTION USED TO
CONJUGATE AZIDE-MODIFIED R8 WITH DSPE-PEGDBCO USING AZIDE-ALKYNE CYCLOADDITION. ........ 38
FIGURE 2.2: EE% OF SIRNA FOLLOWING ALL R8-MODIFICATION TECHNIQUES AS COMPARED TO PLP
CONTROL USING CA2+-MEDIATED ETOH INJECTION METHOD. ..................................................................... 44
FIGURE 2.3A: COMPARISON OF SIRNA EE% IN PLP AND R8-PLP ASSEMBLIES WITH VARIED AMOUNTS OF
CALCIUM DURING INJECTION. ................................................................................................................................ 47
FIGURE 2.3B: COMPARISON OF PDI UPON PLP AND R8-PLP ASSEMBLY USING 0-50 MM [CA2+]. .................... 47
FIGURE 2.3C: COMPARISON OF AVERAGE SIZE (D.NM) UPON PLP AND R8-PLP ASSEMBLY USING 0-50 MM
[CA2+]....................................................................................................................................................................... 48
FIGURE 2.4A: COMPARISON OF SIRNA EE% IN R8-PLP ASSEMBLIES WITH VARIED LIPID:SIRNA (WT-TO-WT). 48
FIGURE 2.4B: PHYSICAL CONFIRMATION OF EE% USING SIRNA GEL EXCLUSION ASSAYS. ................................... 49
FIGURE 2.5A: HEPARIN DISPLACEMENT ASSAY THAT INDICATES THE MINIMUM AMOUNT OF [HEPARIN] TO
REMOVE ALL OUTER-ASSOCIATED SIRNA (WHITE BOX; 100UG/ML)................................................................ 50
FIGURE 2.5B: GEL EXCLUSION/HEPARIN DISPLACEMENT ASSAYS USED TO CHARACTERIZE COMPLEXATION OF
SIRNA WITH R8-PLP ASSEMBLIES........................................................................................................................... 50
FIGURE 2.6A: RNASE STABILITY ASSAY INDICATING THE MINIMUM AMOUNT OF RNASE A REQUIRED TO
DIGEST ALL FREE SIRNA USED FOR ASSAY (WHITE BOX; 0.5 UG/ML)................................................................ 51
FIGURE 2.6B: RNASE STABILITY ASSAY SHOWING NEARLY COMPLETE PROTECTION OF SIRNA-LOADED R8PLPS. ........................................................................................................................................................................... 52
FIGURE 2.7A: COMPARISON OF SIRNA EE% WITH VARIED INJECTION RATES DURING ETOH INJECTION
ASSEMBLY OF R8-PLPS WITH 10:1 LIPID:SIRNA. .................................................................................................. 53
FIGURE 2.7B: COMPARISON OF PDI UPON R8-PLP ASSEMBLY USING VARIED INJECTION RATES (P=NS VS ALL
GROUPS; N=3) .......................................................................................................................................................... 54
xi

FIGURE 2.7C: COMPARISON OF AVERAGE SIZE (D.NM) UPON R8-PLP ASSEMBLY USING VARIED INJECTION
RATES. ......................................................................................................................................................................... 54
FIGURE 2.8: QUALITATIVE FLUORESCENT IMAGES OF HASMCS TREATED WITH R8-PLP ASSEMBLIES WITH
10MOL% STR-R8 AND PLP CONTROLS AT 30 MINS AND 24 HOURS. ............................................................. 55
FIGURE 2.9: SCHEMATIC ILLUSTRATION OF EMPIRICALLY DERIVED CA2+-MEDIATED ETOH INJECTION
TECHNIQUE USED TO ASSEMBLE NONCATIONIC R8-MODIFIED PLPS WITH NEARLY COMPLETE SIRNA EE%
AND ENHANCED CELL ASSOCIATION. ................................................................................................................... 62
FIGURE 3.1: ILLUSTRATION OF LIPID CONSTITUENTS AND THEIR ASSEMBLY WITHIN IN LIPOSOME
CLASSIFICATION USED FOR EXPERIMENTAL ANALYSIS. ........................................................................................ 67
FIGURE 3.2: SCANNING TRANSMISSION ELECTRON MICROSCOPY (STEM) IMAGES CONFIRMING LIPOSOME
MORPHOLOGY AND LAMELLARITY. ........................................................................................................................ 73
FIGURE 3.3: GRAPH SHOWING INCREASED SIRNA ENCAPSULATION WITH INCREASING MOL% OF STR-R8. ... 74
FIGURE 3.4: CYTOTOXICITY OF R8-PLPS WITH INCREASING MOL% R8 AS COMPARED TO PLP AND CLP
CONTROLS................................................................................................................................................................. 76
FIGURE 3.5: GRAPH OF CELL ASSOCIATION OF R8-PLPS AS COMPARED TO CLPS AND NORMALIZED TO PLPS.
.................................................................................................................................................................................... 77
FIGURE 3.6: GRAPH OF SILENCING EFFICIENCY OF R8-PLP SIRNA COMPARED CLP-LOADED SIRNA. .............. 79
FIGURE 3.7: GRAPH OF SILENCING EFFICIENCY OF R8-PLP-LOADED SIRNA COMPARED TO NC SIRNA. ......... 80
FIGURE 4.1: COMPARISON OF AVERAGE SIZE (D.NM) AS A RESULT OF VAPG INCORPORATION INTO PLPS
USING PRE-INSERTION AND POST-INSERTION TECHNIQUES. ............................................................................. 95
FIGURE 4.2: COMPARISON OF POLYDISPERSITY INDEX (PDI) AS A RESULT OF VAPG INCORPORATION INTO
PLPS USING PRE-INSERTION AND POST-INSERTION TECHNIQUES..................................................................... 96
FIGURE 4.3: COMPARISON OF AVERAGE SIZE (D.NM) AS A RESULT OF REDV INCORPORATION INTO PLPS
USING PRE-INSERTION TECHNIQUE. ....................................................................................................................... 96
FIGURE 4.4: COMPARISON OF AVERAGE SIZE (D.NM) AS A RESULT OF REDV INCORPORATION INTO PLPS
USING PRE-INSERTION TECHNIQUE. ....................................................................................................................... 97
FIGURE 4.5: STEM IMAGES OF SMC-PLPS MODIFIED WITH 5 MOL % VAPG........................................................... 97
FIGURE 4.6: THE RELATIVE CELL ASSOCIATION OF VAPG MODIFIED CTP-PLPS COMPARED IN HASMCS AND
HAECS. ...................................................................................................................................................................... 99
FIGURE 4.7: THE RELATIVE CELL ASSOCIATION OF VAPG MODIFIED CTP-PLPS USING POST-INSERTION
TECHNIQUE COMPARED IN VSMCS AND VECS................................................................................................ 100
FIGURE 4.8: THE RELATIVE CELL ASSOCIATION OF REDV MODIFIED CTP-PLPS USING PRE-INSERTION
COMPARED IN VSMCS AND VECS AFTER 1 HOUR TREATMENT..................................................................... 101
FIGURE 4.9: THE RELATIVE CELL ASSOCIATION OF REDV MODIFIED CTP-PLPS SING PRE-INSERTION COMPARED
IN VSMCS AND VECS AFTER 4 HOUR TREATMENT.......................................................................................... 103

xii

CHAPTER 1: Introduction

1

1.1 Overview
As our society ages, peripheral vascular disease (PVD) is increasingly problematic, and
remains a major risk factor contributing to stroke and cardiovascular disease.1 In severe or
complex forms of PVD, surgeons have typically relied on surgical bypass procedures for vessel
revascularization. Fortunately, advanced technology has given rise to endovascular procedures
with comparable success rates and fewer patient risks compared to surgical revascularization.2
Unfortunately, a gold standard intervention is still elusive due to common occurrence of
neointima formation and late vessel restenosis induced by endovascular angioplasty, atherectomy,
and stenting procedures.
Gene therapy has emerged as a promising therapeutic modality in the treatment of a
variety of disease pathologies. A dual gene delivery strategy aimed at reducing neointima
formation and regenerating injured endothelium provides an encouraging pharmacological
approach when implemented in conjunction with surgical and endovascular interventions.3 This
combinatorial gene therapy approach could improve long-term outcomes of patients undergoing
revascularization procedures for PVD, while also limiting further medical interventions, and
significantly reducing PVD-associated costs.
Many gene targets have been elucidated for modulation in the prevention of late vessel
restenosis in a surgical setting, which includes matrix metalloproteinases (MMPs), transforming
growth factor-beta (TGF-β1), and nitric oxide synthase (NOS).4 However, the primary hurdle of
effective gene therapy is the accessibility of a safe and efficacious delivery system.

The

preponderance of evidence shows liposomes to be promising nonviral gene vectors due to
biocompatibility and reduced toxicity profile compared to viral and polymeric vectors.5 Liposomal
2

nanoparticles also exhibit multifunctional potential for targeted gene therapy applications through
lipid surface modifications.6 Due to these advantageous characteristics and validated
pharmacokinetic superiority compared to other common gene vectors, the volume of drug
delivery research in gene therapy continues to shift towards liposomal delivery systems (LDS).
The research herein is a proof-of-concept approach that lays the foundation for the
development of a liposomal gene therapy platform aimed at the efficient and cell-type specific
delivery of siRNA to vascular smooth muscle cells (VSMCs) and vascular endothelial cells (VECs),
respectively. This platform could provide a translational avenue towards the ultimate goal of
delivering gene therapeutics to vascular injury sites in order to inhibit neointima formation and
improve long-term outcomes of surgical interventions performed in vascular disease. This
project is interdisciplinary in nature, which requires the discussion of a variety of academic
research areas. This includes peripheral arterial disease (PAD), mechanisms of atherosclerosis
development, surgical and pharmacological interventions for PAD, and the pathophysiology of
restenosis. Current developments in modern gene therapy and liposomal delivery systems will
also be discussed. The specific aims of this study conclude the introductory chapter.
1.2 Introduction to Peripheral Arterial Disease
PAD affects over 200 million people worldwide, and is the leading cause of disability in
people over the age of 60.7 PAD is the most common form of PVD, and is defined as the
atherogenic progression of disease in arterial vasculature whereby oxygenated blood flow is
occluded to the extremities. PAD is most often caused by atherosclerosis, but can include
aneurysms, thromboembolisms, congenital defects, chronic inflammation, and traumatic injury.8
For the purposes of this dissertation, the term PAD will strictly refer to atherosclerotic
3

pathological processes that affect normal function of the aorta, its visceral branch arteries, and
the arteries of the lower extremity. Progression of occlusive arterial flow in PAD shown in Figure
1.1 is associated with deficits in quality of life, reduction of functional capacity, limb amputation,
and often signals systemic atherosclerosis development.9 In fact, myocardial infarction and stroke
are more common in PAD patients than major adverse limb events (i.e. limb amputation).10 For
this reason, early diagnosis of PAD is crucial, and it should be assumed that PAD patients require
aggressive medical interventions to prevent secondary cardiovascular and cerebrovascular events.
1.2.1 Anatomy of the Vessel Wall
Restenosis is defined as the “loss of greater or equal to 50% of the gain produced at
angioplasty or a >50% stenosis at follow-up angiography.”12 The pathogenesis of restenosis
involves the entire multi-laminar structure of the blood vessel wall. This includes the tunica
adventitia, tunica media, and tunica intima as shown in Figure 1.2. The intimal layer comprises a thin,
continuous layer of VECs anchored to a subendothelial collagenous matrix. VECs help maintain
homeostasis within the vasculature by modulating vascular tone, local cell proliferation and
migration, and regulating extracellular matrix (ECM) deposition.13 Injury to the endothelium
exposes the subendothelial matrix to blood components, which initiates pathogenesis of
atherosclerotic disease. For this reason, reendothelialization is an important pharmacological
strategy for mitigating the progression of vascular disease.
The tunica intima is delineated from the tunica media by the internal elastic lamina (IEL).
The IEL is made up of ECM components such as collagen Type IV, laminin, and proteoglycans.
The underlying tunica media makes up the bulk of the arterial tissue, and is primarily made up of
densely packed VSMCs within an interstitial matrix. It is this muscle layer that provides
4

Figure 1.1: Progression of atherosclerotic development. As the atherosclerotic plaque forms, the artery
experiences increased occlusion. Plaque growth continues leading to eventual plaque rupture and thrombosis.
Adapted from atherosclerosis figure in Mayo Clinic, by Mayo clinic staff, Retrieved January 15, 2019 from
https://www.mayoclinic.org/.11 Copyright 2019 by Mayo Foundation for Medical Education and Research (MFMER).
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Figure 1.2: Anatomy of the arterial vessel wall. The tunica intima and tunica media is separated by the IEL.
The tunica media and the tunica adventitia are separated by the EEL. Adapted from Human Anatomy and Physiology,
11th Edition (pg. 709), by E. N. Marieb, 2019, New York, NY: Pearson Inc. Copyright 2018.
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contraction and relaxation functionality to blood vessels to maintain adequate blood flow and
pressure. In normal, healthy vessels, VSMCs exhibit a quiescent, non-proliferative phenotype.14
When exposed to inflammatory factors and vascular injury, VSMCs can switch from a contractile
phenotype to a synthetic phenotype.15 VSMCs of a synthetic phenotype exhibit substantial
increase in migratory and proliferative potential, and have been shown to contribute to neointima
formation and vascular disease progression. Due to the acute response of VSMCs to a synthetic
phenotype after surgically-induced injury, VSMC proliferation is the most common therapeutic
target to preserve post-operative lumen diameter and prevent restenosis.
Finally, the outer layer, or tunica adventitia, is comprised mainly of fibroblasts and
perivascular nerves within a collagen-rich matrix. The adventitia is delineated from the medial
layer by the external elastic lamina (EEL).16 This layer has been shown to aid in communication
between VSMCs and VECs, and is also the site of resident immune cells such as macrophages, Tcells, B-cells, mast cells, and dendritic cells.

Although the adventitia is often ignored as a

pharmacological target in vascular disease, this layer is primed for the immune response that is
critical to the pathophysiology of atherosclerotic PAD and restenosis in response to vascular
injury.
1.2.2 Pathogenesis of Atherosclerosis
Atherosclerosis, the primary cause of PAD, is the buildup of subendothelial plaques within
the arterial wall, which leads to thickening and hardening of blood vessels. The pathological
buildup of an atheroma, or fatty plaque, is a slow process that begins in the tunica intima. As
plaque progression proceeds, the intima becomes distorted, resulting in negative remodeling and
lumen diameter loss.17 The major atherosclerotic events are delineated in Figure 1.3, which
7

illustrates the chronic progression of atherogenesis and potential critical outcomes. Ultimately,
patients with these complicated lesions can experience potentially lethal ischemia and thrombotic
occlusion of arteries supplying blood to the heart, brain, legs, and other major organs. The
presence of atherosclerotic plaques in PAD typically signals systemic disease burden, therefore,
it is important to identify and treat PAD patients early in disease progression in order to prevent
more serious cardiovascular and cerebrovascular issues.
First, the intimal layer of the vessel is damaged, resulting in endothelial dysfunction. This
initial process can begin in childhood and is precipitated by a host of risk factors including
hypertension, dyslipidemia, diabetes, smoking, hemodynamic factors, and inflammation. As
dysfunction of the endothelium ensues, the inflammatory process in atherosclerosis is initiated.
This process typically originates as platelet adherence and monocyte infiltration within the
compromised endothelium. Next, circulating cholesterol bound to low density lipoprotein (LDL)
begins to cross the endothelial barrier into the intima where it accumulates and becomes oxidized.
Upregulation of monocyte adhesion molecules (MAM), such as P-selectin and vascular cell
adhesion molecule (VCAM-1), leads to enhanced entry of inflammatory cells within the vessel
wall.

Monocyte infiltration and cytokine production is continuous throughout disease

progression, which maintains chronic activity of proinflammatory cascade. Invading and activated
resident immune cells upregulate growth factor expression, which promotes VSMC migration
and proliferation within the intimal layer. Eventually, monocytes differentiate into macrophages
within the vessel wall, which slowly absorb oxidized LDL components leading to foam cell
formation. Finally, as these macrophages undergo apoptosis and dump their cellular debris, a
lipid-rich, fibrous cap begins to form through unregulated MMP expression and excessive ECM
8

Figure 1.3: Illustration of major cellular events and possible critical outcomes of atherogenesis.
Chronic exposure to major risk factors for atherosclerosis leads to endothelial damage. LDL begins to attach to
dysfunctional endothelium and accumulate within intimal layer. Monocytes are also attracted to lesion site by
monocyte adhesion molecules and cytokine production. Once monocytes infiltrate the lesion, they differentiate into
macrophages and engulf lipid-rich particles within plaque forming “foam cells”. As foam cell growth continues, a
fibrous cap is formed. Continuous ECM remodeling leads to vulnerability and eventual plaque rupture. This can
lead to critical stenosis, thrombus occlusion, or aneurysmal rupture. Adapted from “Biomarkers of Atherosclerotic
Plaque Instability and Rupture,” by W. Koenig and N. Khuseyinova, 2006, Arteriosclerosis, Thrombosis, and Vascular
Biology, 27;1, p. 15-26, Copyright 2006 by American Heart Association.
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remodeling within the plaque. Chronic atherogenesis can eventually lead to plaque vulnerability
where thrombosis, plaque rupture, or aneurysmal rupture may ensue.18
1.2.3 Treatment of Atherosclerotic Lesions
The treatment of atherosclerotic peripheral artery occlusion typically begins with noninvasive interventions like exercise prescription and pharmacological approaches. The goal of
these interventions is to relieve pain, improve exercise tolerance, mitigate progressive artery
occlusion, and prevent dangerous secondary cerebrovascular and cardiovascular events.
Examples of medications to treat PAD include anticlotting agents, statins to lower cholesterol,
and medications for hypertension (i.e. beta-blockers, angiotensin converting enzyme inhibitors,
calcium channel blockers, etc.). Adverse lifestyle habits may also be addressed such as diet,
exercise, smoking, and sleep schedule.19 Once conservative strategies fail, the patient is typically
referred for surgical revascularization through surgical bypass or endovascular interventions. The
pros and cons of these two surgical options are compared in Figure 1.4.
Surgical intervention for PAD involves the use of an autologous vein graft or a synthetic
graft (i.e. Polytetrafluoroethylene) as a conduit, which is anastomosed into the diseased
vasculature, bypassing the arterial occlusion and revascularizing distal areas to the lesion site.
Long-term patency rates are comparable to endovascular procedures, especially when using
autologous grafts. However, a recent retrospective meta-analysis has shown that there is no
significant difference in amputation-free survival or all-cause mortality when comparing surgical
bypass to endovascular interventions.20 For this reason, along with minimal risks to patient,
percutaneous endovascular procedures appear to be the most cost-effective and safest surgical
option for PAD intervention.
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Figure 1.4: Surgical bypass and percutaneous transluminal angioplasty revascularization procedures are compared.

Undeniably, endovascular approaches have become increasingly popular over the past 20
years due to simplicity and continued advancements in surgical technology.

Percutaneous

transluminal angioplasty (PTA) is a minimally invasive endovascular procedure commonly
administered in the treatment of PAD. PTA involves the utilization of a catheter-guided balloon
that is inflated at the atherosclerotic lesion site, pressing the plaque into the artery wall in order
to expand the arterial lumen for revascularization.21 Sometimes, stenting, or the implant of a
metallic mesh tube, is used after PTA to hold the artery open after lesion repair. In other cases,
an atherectomy is performed in conjunction with PTA to remove or de-bulk plaque components
at the lesion site with the aid of a mechanical blade or laser. PTA with or without stenting is
associated with shorter recovery times and lower costs for the patient, and preserves
downstream surgical revascularization options that may be needed for coronary interventions.22
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1.3 Restenosis – Vessel Response to Injury
Restenosis is the arterial response to injury that is incurred during surgical and
endovascular procedures. In a clinical setting, restenosis is typically defined as a loss of greater
or equal to 50% of the luminal diameter gain produced by surgical intervention observed in followup angiography.12 Despite advances in biotechnology and pharmacological treatments, late-vessel
restenosis remains a consistent complication in all interventions designed to treat atherosclerotic
lesions. Restenosis also occurs at sites of anastomosis in surgical bypass grafts, and is a leading
cause of graft failure. However, restenosis is more prevalent after percutaneous interventions
due to the mechanical injury inherent in PTA procedures.23

Elimination of restenotic

development would alleviate most complications associated with percutaneous interventions,
thus, reducing the demand for open surgery. For this reason, the focus of this dissertation is
directed towards restenosis as a result of PTA-induced vascular injury.
1.3.1 Intimal Hyperplasia in a Balloon Injury Model
In every form of percutaneous intervention, vascular injury is unavoidable due to the
inherent stress and mechanical stretch placed on the vessel wall during balloon inflation. This
surgically-induced damage is characterized by denudation of the intimal layer comprised of VECs,
exposing the underlying subendothelial matrix and VSMCs to hemodynamic flow.

An

inflammatory cascade ensues, marked initially by platelet adhesion and leukocyte infiltration into
the injured vessel wall. This ultimately triggers VSMC migration and proliferation into the intima,
leading to a gradual thickening of the vessel wall known as intimal hyperplasia (IH; Fig 1.5).24
‘Intimal hyperplasia’ literally is defined as an increase in the number of cells in the intima.
As a clinical term, IH also refers to the simultaneous increase in ECM components and VSMCs
12

Figure 1.5: Diagram of major events in the development of IH-induced restenosis in response to vascular injury
commonly seen in PTA procedures.
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that leads to intimal distortion and reduced vessel lumen diameter. In the case of balloon injury
in PTA, the atherosclerotic plaque is crushed, ruptured, and dislocated, as the entire vessel wall
is mechanically stretched. Platelets contribute to release of basic fibroblast growth factor (bFGF)
and platelet-derived growth factor (PDGF) within the vessel wall. These growth factors, along
with transforming growth factor beta (TGF-β1) and angiotensin, promote VSMC migratory and
proliferative expansion into the intimal layer. PDGF and bFGF also enhance the expression of
MMPs, or proteolytic enzymes capable of degrading the ECM near the cell surface, which further
potentiates the migratory capacity of VSMCs.25 Recent literature has also confirmed that VEC
preservation and regeneration in response to balloon injury is crucial to mitigating VSMC
dysfunction. This is possibly due to nitric oxide (NO) production by resident VECs. Long-term
success without development of restenosis is unattainable when accompanied by delayed
endothelial recovery.26
1.3.2 Timeline of IH-associated Restenosis after Balloon Injury
Stage I – During a PTA procedure with or without stenting, the endothelium is denuded,
exposing the subendothelial matrix and VSMC medial layer. Activated platelets immediately begin
to adhere to injury site, which promotes fibrinogen deposition. This leads to a preliminary fibrinrich thrombus.
Stage II – Thrombosis (48-72 hours): In the days following surgery, thrombus formation begins
to accelerate. Red blood cells aggregate at platelet-rich mass forming fibrin/erythrocyte complex.
The inflammatory process is exponentiated with an upregulation in cytokines, such as MCP-1, IL6, and IL-8. As a result, leukocytes, including neutrophils and macrophages, are recruited to the
initial injury site.
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Stage III – Recruitment Phase (1st week): Monocyte infiltration continues to intensify at
subendothelial thrombus site. Monocytes differentiate into macrophages within the vessel wall.
Immune cell infiltration and local vascular cells begin to release large number of growth factors
such as bFGF, PDGF, TGF- β, and vascular endothelial growth factor (VEGF). This increase in
growth factor expression is concomitant with increased MMP expression. Exposed VSMCs begin
to change from a quiescent phenotype into a synthetic, proliferative phenotype.
Stage IV – Proliferative Phase (1-4 weeks): VSMC residency within the intima continues to
increase. This leads to inward growth of the vessel wall, known as negative remodeling, which
decreases lumen diameter. The intimal layer at the injury site begins to transition from a mural
thrombus into a lesion comprised mostly of neointimal cells.
Stage V – Restenosis (5-12 weeks): ECM deposition accumulates in the intimal layer due to
dysfunctional MMP expression.

Proliferation and migration of VSMCs will continue until

endothelial layer is healed, and inflammatory cascade is halted.

Figure 1.6: Staged development of Intimal Hyperplasia development after PTA-induced injury.27
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1.3.3 Novel Therapeutic Strategies to Prevent PTA-induced Restenosis
There have been several therapeutic strategies developed to mitigate the hyperplastic
response and negative remodeling associated with PTA. Most therapeutic interventions are
aimed at reducing the uncontrolled proliferation of VSMCs after vessel injury. Recently, the use
of coated devices to deliver pharmacologics locally to injury site has increased. This typically
comprises a combinatorial approach that fuses antiproliferative pharmacology with drug-eluting
devices (balloons and stents).28 Other novel approaches include polymeric coated stents and
balloons, endoluminal cryotherapy, and intravascular brachytherapy (IVBT).
The use of intravascular stents began in the 1990’s as small mesh-metal conduits used to
support diseased arteries once cleared of atherosclerotic lesions. Stenting with PTA procedures
is geared towards the prevention of arterial dissection and elastic recoil induced after balloon
injury. Unfortunately, restenosis is still a significant problem, which is sometimes delineated as
in-stent restenosis (ISR).29 Drug-eluting stents (DES) or balloons (DEB) that release
antiproliferative agents into the vessel wall have shown promise in preventing IH-induced
restenosis after PTA. DES and DEB technology often use anti-mitotic agents like paclitaxel and
sirolimus, which are aimed at reducing neointima formation through overall reduction in VSMC
migration and proliferation. Though DES and DEB have decreased acute restenosis and improved
initial success rates of endovascular interventions, they still have a propensity to cause late stent
thrombosis and delayed restenosis months or even years after surgery.30 For this reason, many
vascular surgeons are apprehensive in using DES or DEB due to adverse interactions between
pharmacological agent and human tissue.

16

Polymer coatings have been used in conjunction with DEB and DES with the specific aim
of mimicking the endothelial lining of the vessel wall. By creating a pseudo endothelial layer with
a polymer coating, late vessel thrombotic complications can be prevented. However, clinical
findings show that polymer-coated technology can upregulate genes related to inflammation,
proliferation, thrombosis, and vasoconstriction.31 These unwanted effects can actually increase
rates of restenosis, and have limited the efficacy of polymeric coatings in endovascular
procedures. Current research in this area has moved to the production of biodegradable
polymers, which could improve long-term efficacy of drug-eluting devices in the vasculature.
Endoluminal cryotherapy was developed in 2004 to combat late vessel restenosis
associated with PTA. This therapeutic application involves the use of cold thermal energy in
conjunction with balloon dilatation force. This process essentially “freezes” the vessel wall,
altering elastin fiber behavior and promoting VSMC apoptosis, which reduces the overall VSMC
contribution to the hyperplastic response.32 This therapeutic modality is very appealing to
surgeons due to the fact that permanent implants are unnecessary. Even though primary patency
rates have been encouraging in cryotherapy applications, further randomized-controlled trials are
necessary to confirm long-term success as compared to traditional treatments.
IVBT involves the introduction of radiation to suppress VSMC proliferation and migration
at the target lesion site. This strategy was originally tested in oncological applications but has
recently been explored in vascular surgery. The theory behind the use of IVBT is that proliferating
VSMC cells are more susceptible to radiation damage than normal cells.33 Also, the arterial lesion
induced by PTA is less prone to platelet adhesion and thrombus formation when exposed to
IVBT radiation therapy. When combined with PTA, IVBT has shown a significant reduction in
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restenosis rate at 6-month follow-up when compared to PTA alone. However, this beneficial
effect disappears after 24 months. Further comparative analysis and clinical testing is required to
determine the overall efficacy of this therapeutic modality.34
The main drawback of these novel therapeutic strategies is that they only focus on the
dysfunctional proliferation of VSMC in IH.

Considering the non-specific nature of these

modalities, endothelial recovery is typically compromised.

As mentioned earlier,

reendothelialization is essential to halting long-term neointima formation and thrombosis. An
optimal preventative therapeutic strategy for restenosis after PTA should comprise a cell-type
specific inhibition of migration and proliferation in VSMCs, while promoting intimal healing
through VEC growth and recovery. The use of gene therapy to modulate expression of factors
implicated in IH-induced restenosis in these primary cell types (VSMC vs. VEC) could provide a
path to accomplishing this goal.
1.4 Gene Therapy
Gene therapy is the delivery of genetic material to a cell to correct, replace, augment,
silence, mark, or edit the expression of genes implicated in the pathological presentation of
disease.

There are essentially three phases of gene expression that can be targeted for

therapeutic intervention: transcriptional, post-transcriptional, and post-translational.

Post-

translational modifications are rarely used, and involve epigenetic changes to DNA to alter gene
expression.35 The most well-established form of gene modulation is the delivery of a deficient
gene via a plasmid DNA (pDNA) vector. The plasmid DNA hijacks host cell transcription
machinery once delivered inside the nucleus. Plasmids can be modified in bacterial hosts using
recombinant DNA technology allowing the insertion of virtually any gene sequence. To provide
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functionality for plasmid expression of therapeutic genes, bacterial gene sequences (i.e.
prokaryotic origin of replication, antibiotic resistance markers, etc.) are required, which limits
how small the double-stranded DNA molecule can be. Also, since pDNA molecules require the
use of foreign bacterial sequences, adverse immunogenic responses are common in vivo, which
has limited its translational success.36
RNA medicine comprises a variety of nucleic acid structures including messenger RNA
(mRNA), microRNA (miRNA), transfer RNA (tRNA), short-interfering RNA (siRNA), ribosomal
RNA (rRNA), and short-hairpin RNA (shRNA).37 The use of RNA therapeutics, or short
oligonucleotides, has increased considerably due to the discovery of double stranded RNAmediated interference (RNAi) by Fire and Mello in 1996.38 RNAi methods utilize double-stranded
siRNA to hijack normal cellular machinery within the cell to provide highly specific, posttranscriptional degradation of target mRNA. The small size (<30 nucleotide base pairs) of siRNA
makes it easier to package RNAi technology within common vectors, such as liposomes and
polymers, which can be modified for multifunctional potential. Also, unlike pDNA, siRNA is not
required to enter the nucleus, and can be functionally deployed within the cytosol.
1.4.1 Mechanism of RNA Interference
The RNAi pathway begins when a long double-stranded RNA molecule is cut by an
enzyme called Dicer to create a small nucleotide fragment between 21 and 25 nucleotides long.
These small fragments represent what is known as siRNA, and can be directly introduced to
the cell for improved therapeutic efficacy. These RNA fragments are then loaded into the
RNA-induced silencing complex (RISC), which includes the Argonaute-2 protein (Ago-2). In
this protein complex, the “passenger” strand of the siRNA molecule is removed by Ago-2
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leading to activation of the RISC complex which now contains the single-stranded “guide” RNA
molecule. This complexed “guide” RNA can now interact in a gene specific manner through
complementary base-pairing with its mRNA target. Once bound to its target, the mRNA
molecule is cleaved and degraded by the mature RISC complex before protein translation can
commence.39 In this way, the gene is effectively silenced, which reduces overall expression at
the post-transcriptional level. The mechanism of action of RNAi is illustrated in Figure 1.7.
1.4.2 siRNA Targets in the Treatment of Intimal Hyperplasia
The use of siRNA to silence genes that contribute to neointima formation have been
investigated. Potential targets include growth factors like TGF-β1, connective tissue growth
factor (CTGF), and insulin-like growth factor (IGF-1) to reduce VSMC proliferative cascade within
the injury site. Angiotensin II (AngII), a potent vasoconstrictor and contributor to vascular
remodeling in IH, can be targeted to reduce VSMC growth response to injury. Mitotic promoters
such as C-myc can be inhibited to similarly downregulate VSMC contribution to neointima
formation. Immune mediators such as toll-like receptor 4 (TLR4) and Nuclear factor kappa β
(NF-kβ) are common siRNA targets in IH that have been shown to contribute to dysregulation
of the inflammatory response in vascular injury. MMPs are of particular interest as gene therapy
targets due to their contribution to ECM remodeling and VSMC migration within the intimal
layer.40 Our group has shown that, with the use of siRNA, the inhibition of membrane type 1
metalloproteinase (MT1-MMP) is effective in reducing overall MMP activity and corresponding
VSMC migration and proliferation in vitro.41 There are many other potential targets implicated in
IH development, but the primary hurdle to an adequate gene therapeutic with translational
efficacy is the delivery mechanism. The development of a gene vector that can provide enhanced
20

Figure 1.7: Mechanism of RNAi. DICER cleaves long dsRNA produce siRNA molecule, or synthetic siRNA is
directly introduced into cell. siRNA is loaded into RISC complex, where Ago-2 removes “passenger” strand from
siRNA molecule. Mature RISC complex uses remaining “guide” strand to target gene-specific mRNA. Target mRNA
is cleaved and degraded by mature RISC complex before translation. Adapted from Patenting Interfering RNA (Slide
4), by J. D. Schultz.
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pharmacokinetics and cellular uptake, biocompatibility, low toxicity, and targeted delivery within
the vasculature is required.
1.5 Gene Delivery
The delivery of naked RNA or DNA across the cell membrane is generally inefficient due
to hydrophilic character and molecular instability. To accomplish functional gene transfer, a
carrier, or gene vector is required. Generally, a suitable vector system will include extracellular
targeting and delivery minus unwanted off-site effects. Gene vectors can be given to a patient
directly (in vivo) or to cells that have been extracted and maintained in culture conditions (ex vivo).
Vectors are typically classified as viral or nonviral vectors and the most common vectors are
shown in Figure 1.8.

Figure 1.8: Comparison of commonly used viral and nonviral vectors.
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The first approved gene therapy techniques utilized viral vectors to incorporate
therapeutic genes into cells. Viruses are popular gene vectors due to their inherent ability to
invade cells and deliver nucleic acid cargo into the cellular genome. The most common viral
vectors are derived from lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses
(AAV). Herpes simplex virus-1 and Pox virus have shown some success in vitro, but are less
commonly used.42 Regrettably, viral vectors exhibit toxicity in many cases, and can be highly
immunogenic and unpredictable. The use of many classes of viral vectors is limited in repeat
applications due to increased immune response, which limits overall therapeutic efficacy. Also,
particularly with lentiviral and retroviral applications, insertional mutagenesis is a common
problem, which can exacerbate other medical issues.43 To reduce immunogenic and toxic effects
associated with viral vectors, non-viral approaches have been investigated extensively.
Nonviral vectors are generally classified into three categories: (a) naked DNA delivery,
(b) polymer-based delivery (c) and lipid-based delivery. The use of pDNA is an intriguing nonviral
vector due to its simplicity and ease of production in bacteria.

Therapeutic pDNA molecules

can be manipulated using established recombinant DNA techniques to express specific genes of
interest. Once injected to the target site, it rarely disseminates to distant sites of the body and
does not typically induce antibodies against itself.
Physical methods can also be used to enhance the delivery of naked DNA locally.
Electroporation is a method that uses short bursts of high voltage aimed at the target site to
carry DNA across the cell membrane via temporary pore formation.

Unfortunately,

electroporation is associated with high rates of cell death, and its clinical potential is limited.
Similarly, sonoporation uses ultrasonic frequencies to deliver nucleic acid into cells, but has shown
23

inconsistent results. DNA and RNA can also be complexed with magnetic nanoparticles. In a
process known as magnetofection, a magnet is used to attract these complexes to the tissue site
of interest. Even though advancements have been made in physical methods to aid naked nucleic
acid transfection, unprotected forms of nucleic acid are generally unstable and have limited
application without a delivery vehicle to mitigate nuclease and oxidative degradation.44
Polymeric vectors are often comprised of nucleic acid complexed with polycationic
molecules in what is otherwise known as polyplexes. Some examples of polycationic polymers
used in gene therapy include poly(L-lysine), poly(L-ornithine), both linear and branched
polyethyleneimine

(PEI),

poly(amidoamine)

dendrimers,

and

poly(dimethylaminoethyl

methacrylate). These molecular carriers typically contain positively charged amine groups, and
therefore form electrostatic complexes with negatively charged nucleic acid molecules.45 These
“polyplexes” carry an overall positive charge that enhances its association with cell membranes,
where it eventually becomes endocytosed within an endosome.

Once inside the cell, the

positively charged amino groups and reduced pH contribute to increased osmotic potential and
subsequent endosomal release within the cytosol. Even though polymeric gene transfer has
allowed us to understand feasibility and efficacy of gene therapy candidates, in vivo success is
limited due to systemic toxicity and rapid clearance by the reticuloendothelial system (RES) and
mononuclear phagocytic system (MPS) located primarily in the blood, liver, and spleen.
1.5.1 Introduction to Liposomes
Since their original observation by Alec Bangham over 40 years ago, liposomes have
emerged as the most common nanocarriers for drug delivery applications.46 Liposomes can be
defined as a discrete internal aqueous compartments surrounded by a phospholipid bilayer. The
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phospholipid bilayer mimics the cellular membrane and, therefore, exhibits high biocompatibility
and low toxicity.

Also, liposomes have the ability to encapsulate both hydrophobic and

hydrophilic drugs unlike most other pharmacological nanocarriers. Liposomes are generally
simple to make due to their innate ability to self-assemble, and exert a wide range of
physiochemical and biophysical properties that can be altered to control and accentuate in vitro
and in vivo delivery performance.6 The most intriguing feature of liposomal vectors is their
flexibility of modification and multifunctional potential, which could allow for enhanced
therapeutic index and reduced off-site effects. These liposomal characteristics provide numerous
advantages compared to other gene vectors, which are listed in Figure 1.9.
Our improved understanding of pharmacokinetic properties and modification techniques
with liposomal vectors has led to hundreds of successful in vivo studies. Unfortunately, the benchto-bedside success has progressed much slower than the flux of successful preclinical research.
Figure 1.10 illustrates the exponential increase of published papers related to liposomal drug
delivery along with the sparse sum of FDA-approved liposomal drugs. This discrepancy is even
more intense when only considering liposomal gene vector applications.
Liposomes can be classified into 4 types of liposomal delivery systems (LDS): 1)
Conventional liposomes, 2) Sterically-stabilized liposomes, 3) Ligand-targeted liposome, and 4)
Multifunctional liposomes. Conventional liposomes are typically comprised of phospholipids and
cholesterol in a bilayer that wraps the aqueous core. Conventional liposomes successfully
improved the pharmacokinetics of doxorubicin and amphotericin in the 1980’s. Traditional
liposome formulations are simplistic in nature, and could be directly correlated to a reduction in
toxicity and improved pharmacokinetic profile when compared to free drug alone. Unfortunately,
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Figure 1.9: Advantages of liposomes as pharmaceutical nanocarriers in medicine.

Figure 1.10: Graphical illustration showing exponential growth of liposome-related publications in
medicine as well as the use of computational modeling in developing liposomal drugs. This contrasted
with the small number of approved therapies. Adapted from “Rational design of liposomal drug delivery systems, a
review: Combined experimental and computational studies of lipid membranes, liposomes and their PEGylation,” by
A. Bunker, A. Magarkar, and T. Viitala, 2016, Biochimica et Biohysica Acta, 1858(10), p. 2337. Copyright 2016 by
Elsevier.47

26

conventional liposomes are subject to rapid clearance due to complement activation,
opsonization, and macrophage uptake of the RES within the liver and spleen and are rarely used
in translational models.48
To improve pharmacokinetics of conventional liposomal cargo, sterically stabilized
liposomes were created. Surface-linked polyethylene glycol (PEG) has proven to be the most
optimal method for stabilizing conventional liposomes in vivo.

These so-called PEGylated

liposomes have a steric barrier that produces an aqueous cage around the lipid nanoparticle that
inhibits complement activation, opsonization, and RES clearance. The steric effect of the PEG
shell helps to prolong circulation half-life of liposomal constituents, whereby more drug can reach
its target. Due to the observed ability of these PEGylated liposomes (PLPs) to evade clearance
from circulation, sterically-stabilized liposomes are often referred to as “Stealth” liposomes, and
have been shown to passively accumulate in leaky vasculature of tumor sites due to enhanced
retention and permeation effect (EPR).49 Regrettably, the introduction of PEG on the liposome
surface also reduces cellular uptake of liposomal cargo in what is known as the “PEG dilemma”.
To improve delivery of PLPs, the addition of cell-penetrating peptides (CPPs), such as argininerich peptides (i.e. octaarginine; R8), on the liposome surface is commonly employed.50
The addition of PEG to LDS has also provided a polymeric scaffold to attach functional
ligands on the liposome surface. This offers the potential to target LDS to specific disease sites
in the body. These ligands include peptides, carbohydrates, and antibodies. Specifically, the
conjugation of antibodies (i.e. immunoliposomes) with cell- or tissue-specific binding affinity has
expanded the research area of targeted liposome delivery. However, immunoliposomes still
exhibit high levels of immunogenicity and poor pharmacokinetics seen in conventional liposomes
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and viral vectors. It may be appropriate to elucidate peptides or peptide fragments that exhibit
similar binding affinity and specificity of antibody counterparts.

The integration of these

technologies has led to the development of multifunctional liposomes.

For instance, the

incorporation of PEG into immunoliposomes has improved pharmacokinetics of antibodytargeted LDS. There are a variety of technologies that can be incorporated into liposomes as
shown in Figure 1.11, and the combinatorial possibilities are numerous.
1.5.1.1 Liposomal Gene Therapy
Liposomes are the most widely investigated nonviral gene vectors due to their
biocompatibility and unique ability to encapsulate and protect nucleic acids within an aqueous
environment. Liposomes have been successfully combined with a wide range of nucleic acid
therapies including siRNA, pDNA, miRNA, and modern gene-editing systems. The first liposomal
vectors

were

assembled

using

neutral

phospholipids

like

1,2-Oleoyl-sn-Glycero-3-

phosphocholine (DOPC) and 1,2-Dioleoyl-sn-Glycero-3-phosphoethanolamine (DOPE). Neutral
liposomes enhance the pharmacokinetic capacity and physical stability of nucleic acid delivery, and
were eventually shown to produce significant siRNA-mediated silencing in cancer cells in vivo.
However, the long-term translational success of this liposomal paradigm is limited due to low
levels of transfection and limited encapsulation efficiency nucleic acid cargo.
Soon, synthetic cationic lipids like 1-oleoyl-2-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)
amino]hexanoyl]-3-trimethylammonium propane (DOTAP) were created to help improve nucleic
acid load and cellular uptake of liposomal cargo.

The encapsulation efficiency of cationic

liposomes (CLP) is improved due to the electrostatic complexation of negatively charged nucleic
acid with positively charged lipids like DOTAP. The overall positive charge of the fully assembled
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Figure 1.11: Schematic representation of different classifications of LDS capable of encapsulating
hydrophilic and hydrophobic drugs. 1) Conventional liposomes have a phospholipid bilayer comprised of
charged or neutral lipids and cholesterol. 2) Sterically-stabilized, or PEGylated, liposomes improve pharmacokinetic
characteristics of LDS in vivo. 3) Ligand-targeted liposomes incorporate ligands onto liposome surface or PEG chains
to confer targeting capacity. 4) Multifunctional liposomes can consist of a multitude of ligand applications which
includes imaging agents, targeting ligands, and PEGylation. Adapted from “Ligand-targeted liposome design: challenges
and fundamental considerations,” by G. T. Noble, et al., 2014, Trends in Biotechnology, 32(1), p. 34. Copyright 2014
Elsevier.51
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CLP, or lipoplexes, provides enhanced cellular uptake of nucleic acid cargo due to cellular
association with negatively charged cell membranes.52 However, the charged nature of CLPs
results in unwanted interactions with serum proteins and rapid RES clearance in vivo compared
to neutral liposomes and PLPs. Also, CLPs comprised of synthetic lipids induce cytotoxicity in
vitro and in vivo, and can lead to adverse inflammatory effects. To improve the translational
potential of liposomal gene vectors, further investigation of the assembly and application of
noncationic liposomes is required.53 Figure 1.12 illustrates the lipid classes we used within this
dissertation project, along with nomenclature and chemical structure, to provide comparative
analysis and assembly parameters for development of noncationic liposome platform.
1.6 Research Summary
PTA procedures inherently cause mechanical injury to the vessel marked by denudation
of VECs within the intimal layer. This exposes the underlying medial layer of the vessel to
hemodynamic flow. An acute inflammatory response is triggered through platelet adhesion to
the sub-endothelial matrix, followed by monocyte attachment and infiltration of the vessel wall.
This acute inflammatory response stimulates dysfunctional migration and proliferation of VSMCs
into the intimal layer leading to a gradual thickening of the vessel wall known as IH. Chronic vessel
diameter reduction ensues, clinically referred to as restenosis, eventually requiring surgical
revascularization with increased morbidity rates. Most therapeutic interventions for IH-induced
restenosis are aimed at attenuating VSMC proliferation at the site of the treated lesion. This
approach has been successful in reducing acute intimal thickening. However, chronic restenosis
still occurs in an estimated 60% of patients at 12-month follow-up due to the concomitant
inhibition of VEC recovery inherent in anti-proliferative interventions.54 We postulate that a
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Figure 1.12: Listing of lipid classes used in dissertation with associated nomenclature and structure.
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targeted drug delivery scheme, designed to inhibit VSMC migration and proliferation while
simultaneously enhancing VEC recovery, could prove to be an optimal therapeutic strategy in the
treatment of chronic IH-induced restenosis in a surgical model.
1.6.1 Specific Aims
PLPs have proven to be promising drug delivery agents due to high biocompatibility,
increased half-life in vitro and in vivo, and high degree of flexibility. Specifically, CPPs are short
peptides that can provide enhanced cellular uptake of biomolecular cargo by temporarily
perturbing the cell membrane, leading to direct translocation through the phospholipid bilayer.
Similarly, cell-targeting peptides (CTP) have been conjugated to liposome surfaces to mediate
cell-type specific delivery.

Dual-ligand strategies have been developed for multiple disease

pathologies that employ both CPP and CTP for synergistic cell selectivity and enhanced cytosolic
delivery of gene therapeutics.55 There are two specific aims of this dissertation:
1) We aim to develop a CPP-modified PLP (CPP-PLP) with efficient siRNA encapsulation and
functionally enhanced transfection capacity in vascular cell types.
Hypothesis: An effective noncationic CPP-PLP will provide a liposomal vector with reduced
cytotoxicity and greater translational potential for in vivo applications in the vasculature.
2) We aim to incorporate previously established CTP fragments, specific for VSMC and
VECs, onto lipid surface via click chemistry techniques to impart cell-type specificity of
noncationic PLP assemblies in primary vascular cell types.
Hypothesis: The development of a cell-type specific PLP (CTP-PLP), equipped with VSMCspecific and VEC-specific functional motifs, will provide a drug delivery vehicle capable of
differentially targeting vascular cell types for siRNA delivery.
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CHAPTER 2: The Scalable Assembly of Noncationic
PEGylated Liposomes with Octaarginine-potentiated siRNA
Encapsulation
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The following chapter is currently under consideration for publication in a peer-reviewed
manuscript format. We anticipate publication of this material at a future date.

2.1 Introduction
Ribonucleic acid interference (RNAi) is a biological process that inhibits the posttranscriptional expression of mRNA in the cytoplasm of eukaryotic cells. The gene-specific
nature of small-interfering RNA (siRNA), an active biological molecule of RNAi, provides a
therapeutic avenue for silencing abnormal or unwanted gene expression often exemplified in
vascular disease, cancers, and other rare genetic disorders. However, siRNA is vulnerable to
enzymatic degradation in vivo, and lacks the ability to traverse cell membranes due to large
molecular weight and hydrophilic properties. Therefore, the issue of delivery remains a primary
hurdle to clinical application of siRNA therapeutics.
Liposomes are the most widely studied nonviral gene vectors, with the ability to
encapsulate nucleic acid cargo within an aqueous compartment, protecting it from the external
environment.56 Many multifunctional modification strategies aimed at improving the clinical
efficacy of liposome-mediated gene therapy have been elucidated.57 This includes the
incorporation of polyethylene glycol (PEG) on the surface , resulting in PEGylated liposomes
(PLPs) with increased stability and half-life of siRNA cargo in vivo (2nd generation liposomes),58,59
and the development of ligand-conjugated liposomes for enhanced cell uptake and targeted drug
delivery (3rd generation liposomes).60,61 The use of cationic lipids in liposomal formulations (CLPs)
has helped improve encapsulation of negatively-charged nucleic acid cargo through the
electrostatic-mediated “lipoplexes”.62 However, many synthetic, “unnatural” cationic lipids are
associated with cytotoxicity through toll-like receptor activation,53 mitochondrial membrane
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disruption63, and induction of reactive oxygen species.64 Due to the cytotoxic effects of cationic
liposomes, along with rapid opsonization and macrophage clearance, translational success of CLPmediated gene therapy has been limited despite approval of numerous Phase I clinical trials.48 An
alternative strategy would be constructing nucleic acid lipoplexes with “natural” noncationic
lipids in the presence of divalent cations (i.e. calcium; Ca2+), whereby electrostatic bridging
between the phosphate backbone of nucleic acid and the zwitterionic phospholipid head group
enhances nucleic acid loading during self-assembly.65 However, inadequate cell uptake of standard
PLP assemblies has limited basic science investigations using noncationic lipid formulations.66 Cellpenetrating peptides (CPPs) have been incorporated into PLP bilayers to promote membrane
translocation of liposomal cargo and subsequent cellular uptake.50,67 Unfortunately, due to their
inherent membrane perturbation, the incorporation of CPP-amphiphiles into PLP formulations
often results in cargo leakage and heterogeneous size dispersity as a result of aggregation.68
Consequently, most of the techniques used to assemble CPP-modified PLPs with siRNA or other
nucleic acid cargo are inefficient and costly.
Using octaarginine (R8), a well-established CPP,69 we aimed to elucidate optimal process
parameters required to assemble noncationic, CPP-modified PLPs with efficient siRNA loading
and functionally enhanced transfection capacity. Modification strategies for incorporating R8 into
non-cationic PLPs (R8-PLP) were surveyed to empirically derive an assembly method that
maximizes siRNA retention and encapsulation efficiency (EE%), and produces liposomal
nanoparticles with critical quality attributes necessary for in vivo translation (Table 2.1). This
strategy could provide the ground-breaking advancement required to augment bench-to-bedside
success of liposomal-based RNAi technology.
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Table 2.1: Quality by design approach which provides established criteria, or CQAs, required for effective systemic
administration of liposomal drug delivery systems.

Quality by Design Experimental Approach
Critical Quality Attribute (CQA)

Units
Measured

Desired
Range

Encapsulation Efficiency (EE%)

mol% siRNA

>50%

Zeta Potential (ζ)

millivolts (mV)

<10 mV

Averge Size

diameter (d.nm)

< 100 nm

Polydispersity Index (PDI)

N/A

<0.2

2.2 Materials and Methods
2.2.1 PLP Assembly via Ethanol Injection Technique
Liposome Constituents
All liposome formulation constituents are defined in Table 2.2. Lipids and cholesterol were
purchased from Avanti Polar Lipids (Alabaster, AL, USA). Custom R8 peptide was purchased
with an azido-modified lysine (RRRRRRRRK(N3)-NH2) from P3 Biosystems (Louisville, KY, USA).
STR-R8 was purchased from LifeTein LLC (Somerset, NJ, USA). GAPDH siRNA was purchased
from ThermoFisher Scientific (Waltham, MA, USA).
Liposome Assembly
Base PLP nanoparticles were formed with bulk lipid DOPC:chol at 7:3mol plus 10mol% DSPEPEG, and were assembled using a previously described EtOH injection technique.70 Briefly, lipids
were dissolved in CHCl3, combined as indicated, and dried under N2 gas and vacuum to remove
remaining solvent. Dried lipids were then resuspended in molecular grade 100% EtOH. GAPDH
siRNA at 20-50ug/300uL 10mM Tris-HCl, pH 8.0 with 0-50mM CaCl2 was injected with 2005,000ug total lipid/200uL 100% EtOH, under constant vortexing at room temperature (RT).
36

Table 2.2: Bulk lipid constituents that comprise the liposome formulations used in this study. The appropriate
acronyms are listed for reference.

PLP Formulation Components
Lipid Constituent

Acronym

1,2-dioleoyl-sn-glycero-3-phosphocholine

DOPC

cholesterol

chol

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]

DSPE-PEG

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[dibenzocyclooctyl(polyethylene glycol)-2000]

DSPE-PEGdbco

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
octaarginine (RRRRRRRRK(N3)-NH2)

Rho-PE
R8

Liposomes were purified from EtOH and un-encapsulated siRNA via 24hr dialysis against PBS,
pH 7.4 at 4 °C. Liposomes were extruded using 100nm polycarbonate NanoSizerTM extruders
from T&T Scientific prior to characterization (Knoxville, TN, USA).
2.2.2 CPP Modification via R8 Amphiphile Incorporation
R8-PEG Synthesis
DSPE-PEGdbco, a form of DSPE-PEG with a cyclooctyne modification commonly used in azidealkyne cycloaddition reactions (i.e. click chemistry), was used to form R8-PEG amphiphiles for
PLP incorporation via pre- and post-insertion. Briefly, equimolar azido-modified R8 peptides and
DSPE-PEGdbco were combined at RT under constant agitation for 2hr, according to previously
established reaction conditions.71,72 Mass spectrometry confirmed peptide conjugation and
reaction efficiency (Fig. 2.1).
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Figure 2.1: MALDI-TOF spectroscopy confirmation of successful “click” reaction used to conjugate azide-modified
R8 with DSPE-PEGdbco using azide-alkyne cycloaddition.

Modification of R8-PEG or STR-R8
For all modification strategies, base PLPs were assembled via EtOH injection as described, and
were modified by substituting DSPE-PEG or 7:3 DOPC/chol with R8-PEG or STR-R8 amphiphiles
at equal mol%, respectively. In this way mol% PEG was kept constant across all conditions to
control PEG-mediated membrane stability and assay encapsulate retention as a function of R8
modification alone.
Modification via Pre-insertion
R8-PEG or STR-R8 were combined at 1-10mol% with base PLP lipid constituents at the time of
lipid drying under N2 gas. Likewise, lipid hydration with EtOH was performed in one-step and
all lipid constituents were incorporated at the time of initial liposome assembly. Liposomes were
purified from un-encapsulated siRNA as described, prior to extrusion and characterization.
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Modification via Post-insertion
Base PLPs were assembled as described without the incorporation of R8 amphiphiles. Following
PLP purification by dialysis, R8-PEG or STR-R8 were combined with pre-formed base PLPs and
incubated at 4°C overnight or 37°C for 4 hours, according to previously established conditions
for lipid transfer. A second overnight dialysis was performed following R8-amphiphile insertion
to remove any un-retained siRNA encapsulate, prior to extrusion and characterization.
Modification via Post-conjugation
Base PLPs were assembled as described, without the incorporation of R8, but with DSPEPEGdbco added at the time of lipid drying. Following, purification by dialysis, azido-modified R8
peptides were added in an equimolar amount to DSPE-PEGdbco, and incubated at 4°C overnight
or 37°C for 4 hours, according to previously established parameters of the azide-alkyne
cycloaddition reaction. A second overnight dialysis was performed following R8 conjugation to
remove any un-retained siRNA encapsulate, prior to extrusion and characterization.
2.2.3 Liposome Characterization Studies
Size, Homogeneity, and Charge Characterization
The mean size, associated polydispersity index (PDI), and zeta potential of all liposome
preparations were measured by dynamic light scattering and relative electrophoretic mobility in
water using the Zetasizer Nano ZS instrument (Malvern Instruments Ltd., Worchestershire, UK).
siRNA Encapsulation Efficiency (EE%)
The siRNA encapsulation and retention of all liposome preparations was determined using the
Quant-iT RiboGreen RNA Assay Kit (Thermofisher Scientific). Following purification from un39

encapsulated and/or un-retained siRNA, liposomes were denatured and solubilized in 1% Triton
X-100 at 37°C for 15min to release siRNA cargo. Released siRNA was mixed with RiboGreen
reagent for fluorescent labeling, and emission was read at 525nm.

Fluorescence units of

solubilized liposomes was fit to a known standard curve of siRNA in 1% Triton X-100. EE% of
each liposome formulation was calculated as (pmols siRNA encapsulate / original pmols siRNA
used) x 100.
Gel Electrophoresis
The stability of siRNA-loaded liposomes was assessed using gel electrophoresis techniques.
Stability assays were run using 4% agarose gels with 1ug/mL Ethidium Bromide (EtBr) and 1X
Tris-Boric-EDTA (TBE) buffer for gel preparation and running. All siRNA bands were visualized
by EtBr binding via transillumination through a GFP filter.
Gel Exclusion Assay
For a qualitative analysis of EE%, siRNA-loaded liposome sample aliquots were taken prior to
purification by dialysis, and equal fractions were loaded onto agarose gels. Un-encapsulated, uncomplexed siRNA, free in solution, was ran into gel at 50V for 30mins while liposomes with
encapsulated/complexed siRNA were excluded from gel penetration and isolated to the wells.
To examine total encapsulated siRNA and/or total lipoplexed siRNA, liposome samples were
taken after purification by dialysis, exposed to 1% Triton X-100 and 100 ug/mL heparin to
denature liposome nanoparticles and release all complexed siRNA, and equal fraction were
loaded and ran as described.
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Heparin Displacement Assay
siRNA-loaded liposomes from 100:1 lipid:siRNA wt-to-wt samples were exposed to varying
concentrations of heparin (0-400 ug/mL) for 30 minutes at room temperature. Equal fractions
were loaded onto agarose gels and displaced siRNA was ran into gel at 50V for 30 mins to
determine minimum heparin concentration necessary for complete siRNA displacement from
liposome surface. In follow-on experiments, to examine the proportion of lipoplexed siRNA that
was outer associated and vulnerable to heparin displacement, liposome samples were taken after
purification by dialysis, exposed to 100ug/mL heparin, and equal fractions were loaded and ran as
described. To examine total encapsulated siRNA and/or total lipoplexed siRNA, liposome
samples were taken after purification by dialysis, exposed to 1% Triton X-100 and 100 ug/mL
heparin to denature liposome nanoparticles and release all complexed siRNA, and equal fractions
were loaded and ran as described.
RNase Stability Assay
Free siRNA controls were exposed to varying concentrations of RNase A enzyme (0.001100ug/ml) for 30mins at 37°C to determine minimum RNase necessary for complete siRNA
degradation.

In follow-on experiments, siRNA-loaded liposomes were prepared with and

without the exposure to 0.5ug/mL RNase A, RNase digestion was stopped by flash freezing in
liquid N2, and liposome samples were exposed to 1% Triton X-100 and 100 ug/mL heparin to
denature liposome nanoparticles and release all complexed siRNA. The protection of outer
associated siRNA demonstrated via heparin displacement was validated by the protection from
RNase enzyme degradation compared to the degradation of free siRNA controls.
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2.2.4 Vascular Smooth Muscle Cell Culture
Human aortic smooth muscle cells (HASMCs) were obtained from LifeLine Cell
Technology (Walkersville, MD) as cryopreserved primary cultures of 49yr old male single-donor
cells. Cells were incubated at 37°C in an environment of 5% CO2 and 95% humidity and grown
in VascuLife growth medium (VascuLife Basal Medium + VascuLife smooth muscle cell supplement
kit + gentamyocin/amphotericin; LifeLine Cell Technology).

Prior to experimental use, a

quiescent state was induced using Dulbecco's Modified Eagle Medium (DMEM; Thermofisher
Scientific) + gentamyocin/amphotericin overnight.
2.2.5 Cell Association Studies
To measure cell association, liposomes were assembled as described with the addition of
Rho-PE at 0.5mol%. At ~80% confluency, HASMCs were treated with Rhodamine-labeled neutral
PLPs and R8-PLP groups at 100uM total lipid in DMEM. After 30min and 24hr liposome exposure,
cells were washed three times in PBS and qualitatively imaged by fluorescent microscopy. Images
were acquired with a Texas Red fluorescent filter at 400X under 400msec exposure across all
groups.
2.2.6 Statistical Analysis
All data are reported as mean ± SEM. Statistical analyses were performed using Student’s
t-test or one-way ANOVA and a post-hoc Student-Newman-Keuls test using SPSS 25 software
(Systat Software, Inc., San Jose, CA). Probability (P) values ≤0.05 were considered to be significant.
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2.3 Results
2.3.1 Incorporation of R8-PEG via Pre-insertion, Post-insertion, and Postconjugation Resulted in Significant siRNA Leakage and Reduced Total siRNA
Retention.
Modification of neutral PLPs with 5mol% R8-PEG via post-insertion at 4°C and 37°C, and
via post-conjugation at 4°C and 37°C resulted in 5.11±1.64%, 1.63±0.89, 6.66±2.80%, and
4.98±1.78% final siRNA EE%, respectively (Table 2.3, Fig. 2.2). Pre-insertion of 5mol% R8-PEG
resulted in 16.61±7.06% total siRNA retention, significantly higher than all other R8-PEG groups
(*P<0.05 vs. other R8-PEG groups; n=5-6; Table 2.3, Fig. 2.2), but still significantly lower than
unmodified PLP controls. Additionally, incorporation of R8-PEG by both pre-insertion and
postconjugation resulted in increased nanoparticle size and/or aggregation and increased PDI
(Table 2.4).
2.3.2 Incorporation of STR-R8 via Pre-insertion Resulted in Significantly Enhanced
siRNA Encapsulation and Retention.
Pre-insertion of 5mol% STR-R8 into base PLP resulted in 55.86±6.12% total siRNA
encapsulation, significantly higher than all other STR-R8 modification techniques, all R8-PEG
modification groups, and unmodified PLP controls (**P<0.05 vs. all other groups; n=3-5; Table
2.3, Fig 2.2). Additionally, pre-insertion of STR-R8 resulted in a more favorable nanoparticle
characterization profile of size, PDI, and charge compared to other groups (Table 2.4).
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Figure 2.2: EE% of siRNA following all R8-modification techniques as compared to PLP control using
Ca2+-mediated EtOH injection method. The pre-insertion of R8-PEG results in highest siRNA EE% among all
R8-PEG modification groups. (*P<0.05 vs R8-PEG groups) The pre-insertion of STR-R8 enhanced siRNA EE% above
all R8-PEG and STR-R8 modification groups and PLP control. (**P<0.05 vs. all other groups)

Table 2.3: R8-PLP modification conditions. The siRNA retention and final EE% are listed as a result of R8modification.

R8-PLP Modification Conditions

R8-modification

Liposome
Type

R8-Lipid
Conjugate

Modification
Type

% Leakage

% siRNA
Retention

Final
EE%

PLP

N/A

N/A

N/A

N/A

30.011

Pre-insertion

N/A

N/A

16.614

Post-insertion (4°C)

71.468±4.758

28.532±4.758

5.108

Post-insertion (37°C)

93.394±3.091

6.606±3.091

1.631

R8-PLP

R8-PEG
R8-PEG
R8-PEG
R8-PEG
R8-PEG
STR-R8
STR-R8
STR-R8

Post-conjugation (4°C)

81.615±7.211

18.385±7.211

6.661

Post-conjugation (37°C)

79.386±10.866

20.614±10.866

4.984

Pre-insertion

N/A

N/A

55.856

Post-insertion (4°C)

95.296±2.000

0.522±.195

0.522

Post-insertion (37°C)

97.448±1.472

0.256±.159

0.256
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Table 2.4: R8-PLP modification conditions. Size, PDI, and zeta potential are measured before and after R8modification.

R8-PLP Modification
Conditions
Liposome R8-Lipid
Type
Conjugate
PLP

N/A

N/A

R8-PEG

Pre-insertion

R8-PEG
R8-PEG
R8-PLP

Modification
Type

R8-PEG
R8-PEG
STR-R8
STR-R8
STR-R8

Post-insertion
(4°C)
Post-insertion
(37°C)
Post-conjugation
(4°C)
Post-conjugation
(37°C)
Pre-insertion
Post-insertion
(4°C)
Post-insertion
(37°C)

Pre-modification
Size
(d.nm)

PDI

55.836±5.003 .251±.035
N/A

N/A

Post-modification

Zeta
Potential Size (d.nm) PDI
(mV)

Zeta
Potential
(mV)

9.736±1.024

55.836±5.003 .251±.035

9.736±1.024

820.842±375.680 .521±.126

9.934±1.436

N/A

58.318±1.745 .176±.012 10.208±1.164

68.012±5.881

0.217

10.720±2.153

61.749±3.174 .222±.021 10.698±1.484

72.546±5.449

0.180

11.916±1.445

59.702±6.139 .211±.045 10.436±1.439

176.778±47.892

0.313

10.640±1.271

55.982±5.470 .210±.043 10.574±1.493

172.398±52.063

0.354

9.106±.940

49.650±1.77

.220±.006

7.40±1.90

N/A

N/A

N/A

51.140±.973 .162±.012

1.54±6.870

53.740±2.368 .211±.022 13.700±2.633

49.000±1.752 .206±.001

8.54±2.350

48.830±1.995 .206±.003
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12.100±.551

2.3.3 Ca2+-mediated EtOH injection of R8-PLPs Resulted in Homogenous Liposome
Samples Between 50-60nm with Increased siRNA Retention and EE%.
We have previously reported that STR-R8 increases EE% in a dose dependent manner,
with 10mol% resulting in the highest of all tested modification levels.73 Here 10mol% STR-R8 was
pre-inserted into our R8-PLP assembly, both with and without the presence of Ca2+ at injection.
STR-R8 incorporation without calcium results in EE% of 35.24±2.18%, while the addition of 10mM
Ca2+ significantly increased EE% to 66.28±9.14% (*P<0.05 vs. 0mM Ca2+; n=4; Fig. 2.3A). The
addition of 20-50mM Ca2+ also increased EE% above 0nM, but not to a degree greater than 10mM.
Therefore, R8-PLP siRNA EE% is synergistically enhanced by STR-R8 incorporation and assembly
in the presence of calcium. Additionally, the combinatorial addition of Ca2+ and STR-R8 had no
effect on nanoparticle size, with all liposome groups at 50-60nm in diameter, while samples had
a slightly elevated size distribution compared to PLP controls, but PDI values still <0.25 (Fig. 2.3B
and 2.3C).
2.3.4 Increasing Lipid:siRNA Enhanced R8-PLP EE% to ~100%.
Using the empirically defined assembly parameters for the incorporation of 10mol% STRR8 via pre-insertion in the presence of 10mM Ca2+ at injection, the effect of lipid:siRNA wt-to-wt
ratio was tested from 5:1-100:1. Ratios of 5, 10, 20, 50, and 100:1 achieved EE% of 59.31±4.26%,
77.22±3.42%, 80.64±2.36%, 90.62±4.76%, and ***97.06±5.34%, respectively (***P<0.05 vs. all
groups ≤20:1; n=6; Fig. 2.4A). Gel exclusion assays ran on unpurified liposome samples showed
siRNA bands of decreasing intensity, representing decreasing amounts of un-encapsulated, uncomplexed siRNA with increased lipid:siRNA (Fig. 2.4B). Notably, the siRNA band representing
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Figure 2.3A: Comparison of siRNA EE% in PLP and R8-PLP assemblies with varied amounts of calcium during
injection. The addition of 10mM calcium enhanced siRNA EE% PLP and R8-PLP controls with no calcium. (*P<0.05
vs. 0mM calcium in PLP assembly; **P<0.05 vs. 0mM calcium in R8-PLP assembly)

Figure 2.3B: Comparison of PDI upon PLP and R8-PLP assembly using 0-50 mM [Ca2+].
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Figure 2.3C: Comparison of average size (d.nm) upon PLP and R8-PLP assembly using 0-50 mM [Ca2+].

Figure 2.4A: Comparison of siRNA EE% in R8-PLP assemblies with varied lipid:siRNA (wt-to-wt). The 20:1
lipid:siRNA assembly group showed significantly higher EE% than the 5:1 lipid:siRNA group (*P<0.05 vs. 5:1; P=NS
vs. 10:1). The 50:1 lipid:siRNA assembly group exhibited EE% significantly higher than the 5:1 lipid:siRNA group
(**P<0.05 vs. 10:1; P=NS vs. 20:1). The 100:1 lipid:siRNA assembly group showed significantly higher EE% than the
20:1 lipid:siRNA group (***P<0.05 vs. 20:1; P=NS vs. 50:1).
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Figure 2.4B: Physical confirmation of EE% using siRNA gel exclusion assays. R8-PLPs of varying lipid:siRNA wt-towt ratio were run on 4% agarose gels stained for siRNA content using ethidium bromide. The siRNA band becomes
more faint with increasing lipid:siRNA which indicates, via gel exclusion, increasing EE%.

the 100:1 sample was fully excluded from the gel, indicating ~100% complexation of siRNA with
the R8-PLP nanoparticles (Fig. 2.4B).
2.3.5 Partial Heparin Displacement Indicated siRNA Complexation to R8-PLP
Surface in Addition to Internalized R8-PLP Entrapment.
Heparin displacement assays using 100:1 R8-PLP samples, assembled as empirically
defined, demonstrated that treatment with 100ug/ml heparin for 30min at RT resulted in maximal
siRNA displacement from the liposome surface (Fig. 2.5A). When lipid:siRNA samples (5:1-100:1)
were treated accordingly for full displacement, faint siRNA bands were present in all samples
with increasing band intensity directly related to increasing lipid:siRNA.

This indicated an

increasing proportion of total siRNA EE% should be attributed to outer associated siRNA on the
R8-PLP surface (Fig. 2.5B.1). When samples were treated with heparin+Triton X-100, for
denaturation and displacement, strong siRNA bands further increased in intensity with increasing
lipid:siRNA (Fig. 2.5B.2), confirming increasing total siRNA EE% with increasing lipid:siRNA.
Additionally, these bands were significantly more intense than equivalent lipid:siRNA samples
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Figure 2.5A: Heparin Displacement Assay that indicates the minimum amount of [heparin] to remove all outerassociated siRNA (white box; 100ug/mL).

Figure 2.5B: Gel exclusion/Heparin Displacement Assays used to characterize complexation of siRNA with R8PLP assemblies. (1) R8-PLP assembly with 100:1 lipid:siRNA was treated 100 ug/mL of Heparin to remove outer
associated siRNA after first dialysis. (2) Equal fraction of R8-PLP assembly was treated with heparin + Triton X-100
detergent to remove all siRNA encapsulated after first dialysis before electrophoresis. These bands represent total
EE% and increase in intensity with increasing lipid:siRNA. R8-PLP assemblies with 100:1 lipid:siRNA were then
treated with 100 ug/mL and dialyzed a second time to remove any outer associated siRNA. (3) These siRNA bands
represent outer-associated siRNA remaining after second dialysis. (4) Equal fraction of R8-PLP assembly was treated
with heparin and Triton X-100. These bands represent EE% of siRNA after removal of outer-associated siRNA from
R8-PLP assembly. These bands also increase in intensity with increasing lipid:siRNA.
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treated with heparin only, indicating the proportion of outer associated siRNA is minimal
compared to total EE%. When lipid:siRNA samples were treated with heparin and re-dialyzed
overnight at 4°C to remove outer siRNA, then retreated with heparin+Triton X-100, siRNA
representing only internal encapsulated siRNA were similar in intensity to lipid:siRNA samples
prior to re-dialysis, indicating the majority of total siRNA encapsulate was internally protected
and retained (Fig. 2.5B.4).
2.3.6

R8-PLP Nanoparticles Sufficiently Protected Encapsulated and Complexed

siRNA Against RNase A Degradation.
RNase stability assays against free siRNA controls demonstrated that treatment with
0.5ug/ml RNase A enzyme for 30mins at 37°C was sufficient for complete degradation (Fig. 2.6A).
When R8-PLPs, assembled as empirically defined at 100:1, were treated with 0.5ug/ml RNase
prior to denaturation, there was no demonstrable siRNA degradation, as evidenced by equivalent
siRNA bands in denatured R8-PLPs without RNase treatment (Fig. 2.6B). Likewise, free siRNA
control samples simultaneously exposed to RNase were completely degraded, indicating
complete RNase protection of encapsulated and/or complexed siRNA by the R8-PLP
nanoparticle.

Figure 2.6A: RNase Stability Assay indicating the minimum amount of RNase A required to digest all free siRNA
used for assay (white box; 0.5 ug/mL).
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Figure 2.6B: RNase stability assay showing nearly complete protection of siRNA-loaded R8-PLPs. The siRNA
bands for R8-PLP assemblies treated and untreated with RNase A are of equal intensity, indicating ~100% protection
of siRNA when exposed to nuclease digestion.

2.3.7 Slower Injection Rates During R8-PLP Assembly Resulted in Increased Sample
Homogeneity but Showed No Correlation to EE%.
Using the empirically defined parameters for R8-PLP assembly, varying the speed of
injection at assembly had no significant effect on EE% (n=4; Fig. 2.7A). Importantly, slower
injection rates resulted in a more homogeneous nanoparticle population, with PDI<0.2 at 0.1 and
0.2ml/min (n=3; Fig. 2.7B). Slower injection rates also resulted in an increased average diameter
of the nanoparticles, but all remained <65nm (n=3; Fig. 2.7C).
2.3.8 R8-PLP Nanoparticles Demonstrated Enhanced Cell Association in vitro.
Qualitative analysis of Rho-PE-labeled liposomes, via fluorescence microscopy, exhibited
enhanced cellular association of R8-PLP nanoparticles after 30min and 24hr of exposure,
compared to PLP controls (Fig. 2.8).

52

Figure 2.7A: Comparison of siRNA EE% with varied injection rates during EtOH injection assembly of R8-PLPs
with 10:1 lipid:siRNA. There were no significant differences in siRNA EE% between injection rate groups (P=NS vs.
all groups; n=3)
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Figure 2.7B: Comparison of PDI upon R8-PLP assembly using varied injection rates (P=NS vs all groups; n=3)

Figure 2.7C: Comparison of average size (d.nm) upon R8-PLP assembly using varied injection rates.
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Figure 2.8: Qualitative fluorescent images of HASMCs treated with R8-PLP assemblies with 10mol% STR-R8 and
PLP controls at 30 mins and 24 hours. 0.5mol% of Rho-DPPE was added to all liposome groups and cells were
treated with 100uM total lipid. Images indicated enhanced cell association of R8-PLPs compared to PLP controls at
both 30 mins and 24 hours.
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2.4 Discussion
Therapeutic strategies utilizing siRNA have been validated in a broad spectrum of disease
pathologies in vitro.74,75 Unfortunately, the clinical success of siRNA-mediated gene therapeutics is
hampered by inadequate delivery technology.76 Liposomes have emerged as the most widely
tested nanocarriers of siRNA due to biocompatibility, flexibility of assembly, and multifunctional
potential.57,77 However, effective liposome-mediated transfection typically requires cationic lipids
to improve nucleic acid EE% and cell associative properties.78 Unfortunately, CLP-induced
cytotoxicity and immunogenicity has limited translational efficacy of liposomal gene therapy in
vivo.79 Therefore, the EE% and cell interactive properties of non-cationic PLPs require
optimization to achieve the translational success that remains elusive in liposome-mediated gene
therapy studies. Here we aimed to establish a noncationic PLP formulation with natural lipid
constituents and surface-conjugated CPP as an alternative transfection agent to traditional CLP
formulations that often fail in downstream gene therapy applications. The development of a
simple, scalable method for assembling noncationic CPP-modified PLPs capable of efficient siRNA
loading and enhanced cell association could provide an ideal drug delivery system for gene
therapy.
R8 is a well-established CPP that can be incorporated into PLP bilayers using R8amphiphiles to expose the active peptide on the liposome surface. Examples of R8-amphiphiles
include R8 conjugated to DSPE-PEG (R8-PEG), R8 anchored to stearic fatty acid (STR-R8), and
others.80,81 Common liposome modification techniques that can be used for R8-amphiphile
incorporation are (1) inclusion of R8-amphiphile during initial liposome assembly (pre-insertion),
(2) insertion of R8 amphiphiles into the bilayers of pre-formed liposomes (post-insertion), and
(3) reacting the R8 peptide with functional groups exposed on the surface of pre-formed
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liposomes utilizing click chemistry techniques (post-conjugation).82,83 However, the optimal
process parameters required to assemble CPP-modified noncationic PLPs with efficient siRNA
loading and functionally enhanced delivery are previously unknown.
Here, we first examined the modification of non-cationic PLPs with R8 by incorporating
R8-PEG into the liposomal formulation via pre-insertion, post-insertion, and post-conjugation
techniques. One liposomal attribute that directly affects drug leakage during ligand modification
is membrane fluidity.84 Therefore, in order to minimize membrane fluidity of pre-formed
liposomes during R8 modifications, we tested post-insertion and post-conjugation efficiency at
4°C in addition to previously established reaction conditions of 37°C.85,86 With 4°C still being
well above phase-transition of liposomes comprised of unsaturated lipids, it was expected that
both 4°C and 37°C would provide the thermal energy required for adequate insertion. This
allowed for the assessment siRNA leakage and retention upon R8 incorporation based on the
effects of temperature on membrane fluidity. As expected, when performing post-insertion at
4°C for increased membrane stability, a slightly higher retention of siRNA was achieved when
compared to post-insertion at 37°C (Table 2.3), but final EE% was still only ~5%. Post-conjugation
is often avoided when dealing with CPPs, due to their membrane perturbing effects and siRNA
leakage upon incorporation. Here we confirmed that using R8 with unnatural lysine(azide)
residues to decorate the surface of pre-formed PLPs by post-conjugation resulted in significant
siRNA leakage irrespective of temperature. In fact, the final siRNA encapsulation for postinsertion and post-conjugation in all conditions was no higher that ~7%, limiting the overall
feasibility of assembling R8-modified PLPs using post-insertion or post-conjugation of R8-PEG.
Ultimately, pre-insertion of R8-PEG resulted in enhanced encapsulation above all other R8-PEG
groups, but the PDI of these liposomes was significantly higher even after extrusion (Fig. 2.2,
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Table 2.4). When conjugated to PEG, peptides have more degrees of freedom compared to
peptides conjugated directly to lipid molecules, due to the many degrees of freedom that the
polyethylene glycol polymer exhibits under physiological conditions.87 It is possible this highly
dynamic scenario of the R8 peptide interferes with liposome assembly when using the preinsertion technique. Therefore, while the encapsulation of siRNA is modestly increased by R8PEG pre-insertion vs. post-insertion or post-conjugation techniques, the efficient assembly of
liposomal siRNA nanocarriers is still compromised due to low overall EE%.
Next we examined the modification of non-cationic PLPs with STR-R8. With R8 anchored
to the stearic fatty acid, the entrapment of liposomal siRNA was highly efficient. Contrary to
pre-insertion using R8-PEG, the pre-insertion of STR-R8 had little effect on size dispersity (PDI
< 0.25) and still resulted in liposomes below 50nm (Table 2.4). Furthermore, pre-insertion of
STR-R8 enhanced the overall encapsulation of siRNA to ~56%, the highest EE% achieved when
comparing all R8-amphiphile incorporation techniques. To our knowledge, there is no established
one-step method to encapsulate siRNA above ~50% efficiency in noncationic PLPs. The method
demonstrated here is a one-step assembly whereby all lipid constituents, including ligandconjugated lipids, are solubilized together in organic solvent prior to injection into aqueous buffer
containing siRNA encapsulate. This one-step assembly method is inherently simpler than postinsertion or post-conjugation techniques, which require multiple assembly and purification steps.
Harashima et al. previously demonstrated the unique ability of STR-R8 to condense nucleic acid
through electrostatic complexation.88 We propose that the enhanced EE% seen in R8-PLPs
assembled via pre-inserted STR-R8 is a result of the condensation of siRNA during liposome
assembly. A portion of the STR-R8 is integrated into the PLP bilayer to help enhance delivery,
but much of it may also promote condensation and enhanced encapsulation of siRNA upon
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incorporation into PLPs. In this way, the STR-R8 moiety provides a bifunctional element to R8PLP assembly and application.
To further elucidate the process parameters for R8-PLP formulation and assembly for
optimal encapsulation of siRNA, we examined the synergistic contribution of Ca2+-mediated
nucleic acid condensation. Similar to previously reported results, EtOH injection of non-modified
PLPs in the presence of Ca2+ enhanced the EE% of siRNA with as little as 10mM Ca2+
(14.03±1.18%) compared to PLPs with no Ca2+ (6.82±1.62%, Fig. 2.3A).70 When assembling R8PLPs with pre-insertion of STR-R8 in the presence of Ca2+ there was a synergistic enhancement
of siRNA EE% with ≥10mM, whereby encapsulation approached ~70% at all concentrations and
no deleterious effect was seen in nanoparticle size or homogeneity (Fig. 2.3A-C). Moving
forward, this one-step assembly technique of R8-PLPs, using STR-R8 modification via preinsertion and 10mM Ca2+ at injection, was utilized to assemble all liposome groups to define
additional assembly parameters for optimized siRNA retention and enhanced cell association. A
schematic representing this empirically defined and modified EtOH injection technique is
presented in Fig. 2.9.
For further optimization of assembly parameters, next siRNA loading and carrying
capacity was examined by varying lipid:siRNA wt-to-wt ratios at injection. We demonstrated
increased siRNA loading with increased lipid:siRNA, where 50:1 and 100:1 lipid:siRNA samples
achieved >90% and >97% EE%, respectively (Fig. 2.4A-B).

In order to differentiate outer

associated vs. inner entrapped siRNA proportions constituting this final EE% value, a series of gel
electrophoresis assays were utilized. When all lipid:siRNA samples (5:1-100:1) were treated with
heparin only for outer siRNA disassociation, faint bands indicated an increasing proportion of
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outer associated siRNA with increasing lipid:siRNA conditions (Fig. 2.5B.1). However, when
equivalent fractions of each lipid:siRNA sample were treated with heparin+Triton to release both
associated and entrapped siRNA, bands of greater intensity were revealed, indicating more siRNA
is entrapped within the liposomal core than that which is associated with the outer surface (Fig.
2.5B.2). Subsequently, when additional equivalent fractions were heparin treated and re-dialyzed
overnight to clear outer associated siRNA from the samples, these re-dialyzed lipid:siRNA
samples were treated with heparin+Triton to release total remaining siRNA encapsulate from
the inner core. These siRNA bands remained nearly as intense as lipid:siRNA samples prior to
re-dialysis, reconfirming that the majority of siRNA encapsulate is protected from heparin
displacement and encapsulated within the liposomal core (Fig. 2.5B.4).
Given that a proportion of the nearly 100% encapsulation efficiency demonstrated here
in our 100:1 sample could be attributed to merely outer associated nucleic acid, one could
postulate that the delivery efficacy of our empirically derived R8-PLP platform described herein
might be overestimated for in vitro and/or in vivo translation due to nucleic acid instability in the
presence of serum. Therefore, to determine R8-PLP stability and siRNA protection, R8-PLPs
with the highest EE% (assembled as described at 100:1) were subjected to RNase A enzymatic
degradation prior to gel electrophoresis. As indicated in Fig. 6B, R8-PLPs exposed to RNase
degradation exhibited siRNA bands of equal intensity to untreated R8-PLP controls, while free
siRNA was completely degraded. This qualitative assay confirmed complete protection of siRNA
when encapsulated within our R8-PLP nanocarrier using the assembly method described herein.
Our ultimate goal is to elucidate the most efficient method for producing CPP-modified
PLPs that have the potential for downstream gene therapy applications.
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To this end our

methodology must have the potential for scalable production and the resultant delivery platform
must demonstrate functionality in a dynamic biological environment. While our laboratory
manually derived and validated many of these specifications, the development of instrumentation
to control these and other parameters is a source of ongoing collaborative efforts among our
group and others. Consequently, the data presented here regarding controlled injection rates
and the absence of a significant effect on EE% (Fig. 2.7A-C) may point to an assembly method that
could be highly scalable for industrial applications. Furthermore, to test the dual-functionality of
the STR-R8 in increasing siRNA EE% while simultaneously enhancing the cell associative
properties noncationic PLP assemblies, HASMCs were treated with R8-PLPs and PLP controls.
Here, Rhodamine-labeled lipid (0.5mol%) was added to PLP and R8-PLP assemblies for liposome
tracking. As revealed through fluorescent analysis, R8-PLPs significantly enhanced cell association
at both 30 mins and 24 hours post treatment compared to unmodified PLP controls. This
preliminary in vitro validation supports the need for further studies of functionality and delivery
efficacy in vitro and in vivo. As such our future assays will focus on the cytotoxicity profiles, in vitro
gene targeting efficacy, in vivo biodistribution analysis, and pharmacokinetic profiling of the R8PLP nanocarrier platform.
In conclusion, our research has demonstrated that the addition of STR-R8 into PLPs
utilizing the pre-insertion technique is a simple and efficient method to produce noncationic CPPmodified liposomes capable of enhanced cell association and optimal siRNA retention (Fig. 2.9).
This development could provide a foundation for future clinical applications of liposomal gene
therapy with greater translational success.
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Figure 2.9: Schematic illustration of empirically derived Ca2+-mediated EtOH injection technique used to assemble
noncationic R8-modified PLPs with nearly complete siRNA EE% and enhanced cell association. These R8-PLP
assemblies are exhibit critical quality attributes required for optimal in vitro performance in vivo translation with an
average size of <100nm in diameter, zeta potential of <10mV, and unilamellar structure.
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CHAPTER 3: Improving the Efficacy of Liposomal-mediated
Vascular Gene Therapy via Lipid Surface Modifications
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The following chapter was published in the Journal of Surgical Research and is reprinted here with
permission from Elsevier.
3.1 Introduction
Currently there are more than 200 million people worldwide with peripheral vascular
disease (PVD).89 As average global life expectancy continues to escalate, the prevalence of PVD
will also continue to rise. Endovascular interventions are low-risk, minimally invasive procedures
that have become increasingly pervasive in the treatment of PVD due to high initial success rates
(>90%).90 Unfortunately, endovascular procedures are linked to higher re-intervention rates for
loss of vessel patency, due to chronic restenosis and injury-induced intimal hyperplasia (IH)
development, typically marked by dysfunctional migration and proliferation of vascular smooth
muscle cells (VSMC) in the vessel wall along with delayed vascular endothelial cell (VEC)
recovery.91 In fact, IH-induced restenosis occurs in greater than 60% of endovascular cases at 12months follow-up, often requiring secondary intervention with increased morbidity and mortality
rates.92,93 An optimal treatment plan to mitigate the development of IH-induced restenosis would
improve long-term primary intervention success rates, and help relieve the clinical and financial
burden of the PVD health epidemic.
RNA interference (RNAi), or the use of short interfering RNA (siRNA) to transiently
attenuate cellular protein expression, shows promise as a gene therapy technology to alter
vascular pathology.94,95 Our lab has previously defined several molecular mechanisms of IH
development that could be potential targets for molecular therapeutics aimed at its attenuation.96102

However, the development of molecular nanocarriers is needed in order to overcome the

unfavorable physiochemical properties that limit intracellular siRNA uptake. Various transfection
agents have been investigated for their application of gene therapy to vascular cell types, including
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polymeric nanoparticles, chemical agents, and viral vectors.103-105 Recently, our group has
successfully deployed multiple classes of biodegradable polymers in the delivery of molecular gene
therapy in vascular cell types and tissue in vitro.106,107 While many of these nanocarriers have shown
efficacy with in vitro transfection, they often fail to translate to an in vivo model due to their
cytotoxicity, adverse immune response, and inefficient biodistribution.106,108 Therefore, the
development of a biocompatible nanocarrier that can provide targeted vascular gene therapy,
without immunological or cytotoxic effects, is needed to provide a drug delivery candidate for
future in vivo testing for the attenuation of IH development in a post-surgical model.
Liposomes are promising drug delivery vehicles due to their biocompatibility, relatively
low cytotoxicity, and flexibility of modification. Liposomal phospholipids are arranged in a bilayer
that forms a spherical nanoparticle mimicking the cell membrane. Cationic liposomes (CLPs),
made with synthetic lipid components, have been successfully used in the delivery of gene
therapeutics in vitro, due to the high loading capacity of negatively charged phosphate groups
present in nucleic acids.79,109 Also, the positive surface charge of CLPs promotes cellular
interaction due to the electrostatic affinity for the negatively charged cell membrane.
Unfortunately, clinical translatability has been limited, as CLPs are often demonstrated to be
cytotoxic and immunogenic when administered in vivo, partially attributable to their synthetic
constituents.110
Neutral liposomes are comprised of naturally occurring phospholipid constituents and
have been modified to improve efficacy as targeted nanocarriers while maintaining a lower
toxicity profile. Polyethyleneglycol (PEG) can be conjugated to the surface of a liposome to
provide “stealth” properties for the nanoparticle. Along with their nanoscale size at <150 nm in
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diameter, PEGylation allows the nanocarrier to avoid opsonization clearance from the blood
stream, increasing the overall half-life of the carrier.5 The most intriguing aspect of neutral
PEGylated liposomes (PLPs) is the flexibility of modification and multifunctional potential provided
by the PEG shell on the liposome surface.

The PEG molecule can provide a scaffold for

conjugation of functional ligands, and various ligand classes can be anchored into the lipid bilayer
via stearylated fatty acids. These modifications can provide functional modalities such as enhanced
intracellular delivery, cell-type specific delivery, triggered release, imaging capabilities, tissue
localization, etc.111 Specifically, cell-penetrating peptides (CPPs) are short peptide fragments that
can enhance cellular uptake of biomolecular cargo.67,112 These peptides are typically cationic in
nature and can locally and temporarily disrupt the lipid bilayer on the cell surface, leading to direct
translocation across the cell membrane.

Here, we aim to establish CPP-modified neutral

liposomes as efficient molecular nanocarriers in VSMCs, with reduced cytotoxicity and enhanced
siRNA delivery as compared to standard CLP formulations previously established in the RNAi
literature. Improving the efficacy of liposome-mediated molecular therapeutics in vascular cell
types, using lipid surface modifications, could lead to a translatable drug delivery platform for
future in vivo application in vascular injury models of disease aimed at the prevention of IH.
3.2 Materials and Methods
3.2.1 Neutral and Cationic Liposome Assembly via EtOH Injection
All liposome constituent acronyms are defined in Table 3.1. Lipids and cholesterol were
purchased from Avanti Polar Lipids (Alabaster, AL, USA). Octaarginine (R8) peptide, a wellestablished CPP that has been shown to enhance cytosolic delivery of PLP contents, was
purchased from LifeTein LLC (Somerset, NJ, USA).112,113 Figure 3.1 illustrates each liposome group
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Table 3.1: Liposome constituents.

Liposome Constituents
Acronym

Lipid Derivative

DOPC

1,2-dioleoyl-sn-glycero-3-phosphocholine

DSPE-PEG

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]

DOTAP

1,2-dioleoyl-3-trimethylammonium-propane

DOPE

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine

Rho-DOPE

N-(lissamine rhodamine B sulfonyl)-1,2-dioleoyl-sn-glycero-3-phosphoethanolamine

Chol

Ovine cholesterol

STR-R8

Stearylated octaarginine

Figure 3.1: Illustration of lipid constituents and their assembly within in liposome classification used for
experimental analysis. Constituent abbreviations defined in Table 3.1.
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and their constituents in schematic form. Neutral PEGylated non-modified liposomes (PLP) were
formed with bulk lipid DOPC:chol at 7:3mol plus 10mol% DSPE-PEG. Neutral PEGylated R8modified liposomes (R8-PLP) were formed with PLP base plus increasing increments of STR-R8
(1-10mol%). Non-PEGylated neutral controls (LP and R8-LP) were formed with identical bulk
lipid base without the addition of DSPE-PEG. PEGylated cationic liposomes (CLP) were formed
with DOTAP:DOPE at 1:1mol plus 10mol% DSPE-PEG.

All liposome formulations were

assembled via the EtOH injection technique previously described 70. Briefly, lipids were dissolved
in CHCl3, combined as indicated, and dried under N2 gas and vacuum to remove remaining
solvent, and then resuspended in molecular grade 100% EtOH. GAPDH or negative control
(NC) siRNA (Thermofisher Scientific, Waltham, MA, USA) at 50ug/300ul 10mM Tris-HCl, pH 8.0
(plus 10nM CaCl2 for neutral formulations) was injected with 125-1000ug total lipid/200uL 100%
EtOH, under constant vortexing at room temp.

Liposomes were then purified from un-

encapsulated siRNA via overnight dialysis against PBS, pH 7.4 at 4 °C and extruded at 100nm
using polycarbonate membranes (Avanti Polar Lipids).
3.2.2 Liposome Characterization Studies
Size and Charge Characterization
The mean size and zeta potential of all liposome preparations were measured in triplicate by
dynamic light scattering and electrophoretic mobility on the Zetasizer Nano ZS instrument
(Malvern Instruments Ltd., Worchestershire, UK).
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Morphological Characterization by Scanning Transmission Electron Microscopy
Liposome morphology and lamellarity were investigated by STEM using a negative-stain method.
Liposomes were applied dropwise to a carbon film coated copper grid and allowed to air dry.
Liposome films were then stained with 2% phosphotungstic acid and air-dried for 1min at room
temp. Samples were visualized with Zeiss Auriga 40 STEM scope, and images were acquired by
SmartSEM image acquisition software (Carl Zeiss, Inc., Oberkochen, Germany).
Encapsulation Efficiency (EE%)
siRNA encapsulation of each preparation was determined using Quant-iT RiboGreen RNA Assay
Kit (Thermofisher Scientific). Briefly, liposomes were solubilized in 1% Triton X-100 at 37°C for
15min to release encapsulated siRNA, mixed 1:1 with RiboGreen reagent for fluorescent labeling
of siRNA, and emission was measured at 525nm. Fluorescence units of solubilized liposomes
were compared to a known standard curve of siRNA in 1% Triton X-100 to determine ug of
siRNA encapsulate. EE% of each liposome formulation was calculated as (ug siRNA encapsulate
/ 50ug total siRNA) x 100.
3.2.3 Vascular Smooth Muscle Cell Culture
Human aortic smooth muscle cells (HASMCs) were obtained from LifeLine Cell
Technology (Walkersville, MD) as cryopreserved primary cultures of 49yr old male singledonor cells. Cells were plated at 1.5x105 cells/well (6-well plate) for gene expression and cell
viability experiments or at 4x104 cells/well (24-well plate) for cell association experiments.
Cells were incubated at 37°C in an environment of 5% CO2 and 95% humidity and grown to 6080% confluency in VascuLife growth medium (VascuLife Basal Medium + VascuLife smooth
muscle cell supplement kit + gentamyocin/amphotericin; LifeLine Cell Technology). Prior to
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experimental use, cells were made quiescent in Dulbecco's Modified Eagle Medium (DMEM;
Thermofisher Scientific) + gentamyocin/amphotericin overnight.
3.2.4 Cytotoxicity Assays
At ~60% confluency, HASMCs were treated with PLPs, R8-PLPs, and CLPs at 200nM
siRNA in DMEM. After 24h treatment, LIVE/DEAD® Viability/Cytotoxicity Kit (Thermofisher
Scientific) was used to determine relative cell toxicity, according to the manufacturer’s
instructions. Briefly, DMEM was removed, cells were washed twice in PBS, and co-stained with
calcein-AM + ethidium homodimer (1ul each /1ml PBS) for 15min at 37°C. Stained cells were
visualized via fluorescein isothiocyanate (FITC; live) and Texas Red (dead) fluorescent filters.
Images were acquired on both filters at 400x using a BX51 Olympus microscope with an Olympus
Q-color camera (Olympus Corporation, Shinjuku, Tokyo, Japan) in three independent fields per
sample. Cells were counted using ImagePro software (Media Cybernetics, Inc., Rockville, MD).
Cellular toxicity was calculated as [dead cell count/(dead cell count +live cell count)] in each
image, triplicates were averaged per independent sample, and the mean normalized to baseline
cell death in non-treated controls of each experimental replicate.
3.2.5 Cell Association Experiments
To measure cell association, liposomes were assembled as described with the addition of
Rho-DOPE at 0.1mol%. At ~80% confluency, HASMCs were treated with Rhodamine-labeled
PLPs, R8-PLPs, and CLPs at 0.2mM total lipid in DMEM. After 24 hour treatment cells were
washed twice in PBS, lysed with 1% Triton X-100, and centrifuged at 12,000 RPM for 5min at 4°C
to remove cell debris. Cell lysates (100ul) were plated in duplicate in 96-well plates, and cell
association of rhodamine-labeled liposomes was determined by fluorimetry at 575nm. Cell
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association was determined by mean arbitrary fluorescence units (AFU) of each sample, minus
baseline fluorescence of non-treated controls receiving no Rhodamine source within each
experimental replicate. For qualitative analysis microscopy images were acquired with a Texas
Red fluorescent filter at 400X under 400msec exposure across all groups.
3.2.6 Liposome Transfection and Gene Expression Analysis
HASMCs were transfected with PLPs, R8-PLPs, and CLPs at 200, 400, and 500nM siRNA
in serum-free DMEM. After 24 hour transfection, DMEM was removed, and cells were incubated
an additional 24h in VascuLife growth medium before collection for quantitative polymerase chain
reaction (qPCR).

All qPCR reagents were obtained from Thermofisher Scientific unless

otherwise noted. Total RNA was isolated using Ambion Paris Kit according to manufacturer’s
instructions, and 200ng was converted to cDNA using the High Capacity RNA-to-cDNA Master
Mix. Two microliters of cDNA transcripts were then amplified by qPCR using the TaqMan®
Gene Expression Master Mix and predesigned TaqMan Gene Expression Assays specific for
human GAPDH on the StepOne PCR system (Applied Biosystems, Foster City, CA, USA). The
comparative cycle threshold method was used to determine relative quantity of GAPDH mRNA
in liposome treated samples compared with non-treated controls (Control) or in samples
receiving encapsulated GAPDH siRNA compared with NC siRNA, as indicated. All mRNA
amounts were normalized to 18S ribosomal RNA as an endogenous control.
3.2.7 Statistical Analysis
All data are reported as mean ± SEM. Statistical analyses were performed using Student’s
t-test or one-way ANOVA and a post-hoc Student-Newman-Keuls test using SigmaStat 3.5
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software (Systat Software, Inc., San Jose, CA). Probability (P) values ≤0.05 were considered to be
significant.
3.3 Results
3.3.1 EtOH Injection Assembly of PLPs, R8-PLPs, and CLPs Results in Nanoparticles
with Similar Physical Characteristics.
STEM images confirm the spherical morphology and unilamellarity of each liposome class
(Fig. 3.2). Dynamic light scattering confirms a narrow size distribution at ~50-150nm following
EtOH injection and extrusion of all liposome classes (Table 3.2). Zeta-potentials, determined
by electrophoretic mobility measurements, demonstrate neutral-low positive charge of PLP and
R8-PLP groups and an increased positive charge of CLPs (Table 3.2).
3.3.2 R8 Modification of PLPs Increases Encapsulation Efficiency of siRNA in a
Concentration Dependent Manner.
EtOH injection assembly of non-modified PLPs results in siRNA encapsulation at
20.0±1.9% using 500ug total lipid / 50 ug siRNA (n=6; Fig 3.3). Addition of STR-R8 at 2.5mol%,
5mol%, and 10%mol increases encapsulation to 63.1±3.8%, 68.0±2.4%, and 73.3±5.0%,
respectively (n=5-6; Fig 3.3). These R8-PLP groups demonstrate an efficiency equivalent to
CLPs (60.3±12.0%; P=NS vs. CLP; n=5-6; Fig 3.3).
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Figure 3.2: Scanning transmission electron microscopy (STEM) images confirming liposome morphology and
lamellarity. A 2% phosphotungstic acid negative-stain method is used to visualize the spherical morphology and
unilamellarity of liposomes assembled using the described EtOH injection assembly technique. Image is
representative of each liposome class. Scale bar = 100nm.

Table 3.2: Liposome characterization.

Liposome Characteristics
Liposome Class

Size (nm)

PDI

Zeta-potential

PLP

41.6±2.8

0.27±0.08

7.1±0.4

R8-PLP 1mol%

44.7±0.9

0.20±0.03

8.6±1.0

R8-PLP 2.5mol%

39.3±1.1

0.16±0.01

7.7±1.3

R8-PLP 5mol%

35.9±1.0

0.15±0.01

8.8±0.6

R8-PLP 10mol%

40.2±3.1

0.31±0.09

10.5±0.2

CLP

37.0±1.8

0.24±0.03

13.7±1.1
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Figure 3.3: Graph showing increased siRNA encapsulation with increasing mol% of STR-R8. siRNA encapsulation
of each liposome formulation was determined using Quant-iT RiboGreen RNA Assay Kit, and encapsulation
efficiency (EE%) was calculated as (ug siRNA encapsulate / 50ug total siRNA) x 100. R8 modification of PLPs increases
EE% of siRNA in a manner equivalent to CLPs. P=NS within groups as indicated, n=5-6.
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3.3.3 Non-cationic Liposomes Exhibited Significantly Less Cytotoxic Effects
Compared to Cationic Liposomes.
Treatment of HASMCs with CLPs at 200nM siRNA increased cell death by 1.99±0.27-fold
compared to baseline death of non-treated controls (*P<0.05 vs. control; n=3-6; Fig 3.4). PLPs
had no effect on baseline cell death of non-treated controls (0.98±0.14 vs. 1.00; P=NS vs. control;
n=3-6). R8 modification of PLPs at 5 and 10mol% demonstrated no significant death over baseline
(1.14±0.18 and 1.19±0.23, respectively; P=NS vs. control; n=3-6; Fig 3.4). PLP and all R8-PLP
groups exhibited significantly lower cytotoxic effect than CLPs (**P<0.05 vs. CLP; n=3-6, Fig 3.4).
3.3.4

R8 Lipid Surface Modification Significantly Increases the Cell Association of

PLPs.
Treatment of HASMCs with CLPs at 0.2mM total lipid resulted in 22.3±4.9-fold increase
in cell association compared to non-modified PLPs (*P<0.05 vs. PLP; n=3; Fig. 3.5). R8
modification at 5 and 10mol% significantly increased cell association compared to non-modified
PLPs (**P<0.05 vs. PLP; n=3, Fig 3.5), with R8-PLP 10mol% resulting in the largest effect at
10.8±2.4-fold increase (***P<0.05 vs. all other R8-PLPs; n=3; Fig 3.5).
3.3.5 Transfection with R8-PLPs, Modified at 10mol% STR-R8, Resulted in
Significant GAPDH silencing, in a Manner Dependent on Lipid-to-siRNA Load
Capacity.
R8-PLP-10mol% liposomes were used to deliver 200nM and 400nM siRNA to cultured
HASMCs at lipid-to-siRNA weight/weight (w:w) ratios of 2.5:1-20:1. Delivery of GAPDH
siRNA at 2.5:1 had no effect on GAPDH expression at either 200nM or 400nM siRNA.
However, 400nM siRNA delivered with 5:1, 10:1, and 20:1 w:w liposomes resulted in significant
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Figure 3.4: Cytotoxicity of R8-PLPs with increasing mol% R8 as compared to PLP and CLP controls.
Cellular toxicity of each liposome formulation was determined by Live/Dead co-stain with calcein-AM and ethidium
homodimer. Cells were visualized and counted under fluorescent microscopy, and toxicity was calculated as [dead
cell count/(dead cell count +live cell count) and normalized to baseline cell death in non-treated controls. PLPs had
no cytotoxic effect, and all R8-PLP groups exhibited significantly lower cytotoxic effect than CLPs. P=NS vs. nontreated control; *P≤0.05 vs. non-treated control; **P≤0.05 vs. CLP; n=3-6.
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Figure 3.5: Graph of cell association of R8-PLPs as compared to CLPs and normalized to PLPs. Liposomes were
assembled as described with the addition of Rho-DOPE at 0.1mol%, and cell association was determined by mean
arbitrary fluorescence units (AFU) of each sample, minus baseline fluorescence of non-treated controls receiving no
Rhodamine source. R8 lipid surface modification at 5 and 10mol% significantly increases cell association compared
to non-modified PLPs. * and **P≤0.05 vs. PLP; ***P≤0.05 vs. all other R8-PLPs; n=3.
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GAPDH silencing when compared to non-treated controls (83±2, 68±10, and 41±7% relative
expression, respectively; *P≤0.05 vs. control (non-treated); **P≤0.05 vs. control and CLP; n=47; Fig 3.6). Furthermore, 200nM siRNA was sufficient for significant GAPDH silencing when
delivered at 10:1 and 20:1 w:w (83±8 and 74±9% relative expression, respectively; *P≤0.05 vs.
control (non-treated); n=4-7; Fig 3.6). To account for any off-target effects resulting from
exposure to nanoparticle constituents alone, expression was also normalized to HASMCs
receiving NC siRNA under identical liposomal delivery conditions. Effective silencing was
confirmed with 400nM GAPDH siRNA at 10:1 and 20:1 w:w delivery when compared to NC
siRNA controls (59±18 and 42±14% relative expression, respectively; *P≤0.05 vs. control (NC
siRNA); n=3-4; Fig 3.7) and with 200nM GAPDH siRNA at 10:1 w:w delivery when compared
to NC siRNA controls (71±8% relative expression; *P≤0.05 vs. control (NC siRNA); n=3-4; Fig
3.7). CLP-mediated delivery also resulted in modest but statistically significant silencing at both
200nM and 400nM (92±4 and 93±5% relative expression vs. non-treated controls or 90±3 and
94±2% relative expression vs. NC siRNA controls; *P≤0.05 vs. controls; n=5-7; Fig 3.6 and 3.7),
while non-modified PLPs had no effect on gene silencing under any condition. Importantly, R8PLP-10mol% formulations demonstrated GAPDH silencing that was significantly better than
CLP-mediated silencing under multiple treatment parameters (**P≤0.05 vs. control and CLP;
n=4-7; Fig 3.6).
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Figure 3.6: Graph of silencing efficiency of R8-PLP siRNA compared CLP-loaded siRNA. R8-PLP-10mol% liposome
transfection demonstrated significant silencing, in a manner dependent on lipid-to-siRNA load capacity when tested
at w:w ratios of 2.5:1-20:1. *P≤0.05 vs. non-treated control; **P≤0.05 vs. control and CLP; n=3-7.
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Figure 3.7: Graph of silencing efficiency of R8-PLP-loaded siRNA compared to NC siRNA. Liposomal mediated
gene silencing was determined by qPCR, using the comparative cycle threshold method to determine relative quantity
of GAPDH mRNA in liposome treated samples compared with non-treated controls (Control) or in samples
receiving encapsulated GAPDH siRNA compared with NC siRNA, as indicated. *P≤0.05 vs. NC siRNA control; n=37.
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3.4 Discussion
Gene therapy has shown promise as a novel therapeutic modality in the treatment of PVD
and IH development.40,114,115 Specifically, RNAi could be used to alter or inhibit vascular
pathologies in a gene-specific manner. An ideal vector for siRNA-mediated gene modulation
would require a molecular carrier capable of enhanced transfection, reduced cytotoxicity, and
increased stability in vitro and in vivo. Successful in vitro gene silencing has been demonstrated in
vascular cell types using viral vectors, cationic polymers, and lipid-based nanoparticles. Cationic
liposomes have been demonstrated as effective molecular carriers for vascular cell types in vitro
due to enhanced association with negatively charged cell membranes, optimal loading efficiency
of siRNA during lipoplex formation, and reduced susceptibility to nuclease activity.116 However,
translational success of cationic liposome-mediated transfection has been limited due to elevated
immunogenicity, cytotoxicity, and hepatic clearance in vivo.117,118 The design of a CPP-modified
neutral liposome, formed with natural lipid constituents, could provide enhanced encapsulation
and cell association properties, while avoiding the adverse cytotoxic effects associated with
cationic lipid nanocarriers.
Here we aimed to compare neutral liposomes, with and without CPP modification, to a
standard CLP formulation frequently described in the RNAi literature, in order to examine their
efficacy as nanocarriers in VSMCs. We utilized a modified EtOH injection technique to assemble
PLPs, R8-PLPs, and CLP groups with encapsulated siRNA as our molecular cargo for delivery (Fig
3.1, Table 3.2). This method proved to be effective in forming unilamellar liposomes with
spherical morphology and a narrow size distribution of <45nm in all groups (PDI≤0.31±0.09; Fig
3.2, Table 3.1). Typically, positively charged lipid nanoparticles, with augmented size (>150 nm),
have reduced half-life due to opsonin-dependent clearance and elevated hepatic removal
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rates.119,120 Previous in vivo studies using liposome-mediated gene therapy have shown neutrallycharged liposomes <100nm in diameter to have increased half-life in vivo.121,122 The size and zeta
potential data presented here validates our modified EtOH injection assembly method as a valid
technique for these in vitro and future in vivo investigations of liposomal nanoparticles.
R8 is a well-established CPP that has been shown to enhance membrane translocation of
a wide variety of biological cargo, including neutral liposomes.88,123,124 To construct CPP-modified
liposomes in this study, STR-R8 was anchored into the lipid bilayer in order to expose R8 on the
liposome surface. Because efficient drug loading of anionic siRNA within neutral PLPs has proven
difficult, it is important to note that we were able to demonstrate enhanced siRNA encapsulation
with STR-R8 incorporation, to a degree equivalent to that of CLPs (Fig 3.3). This enhanced
loading efficiency could be attributed to 1) the Ca2+-modulated condensation of siRNA inherent
in our modified assembly technique, and 2) the cationic nature exhibited by the R8 peptide, which
is attracted to the negatively charged phosphate backbone of the siRNA molecule. In fact,
addition of STR-R8 to the liposomal formulation was associated with a modest increase in overall
membrane zeta-potential, slightly skewing the charge of our CPP-modified liposome toward a
more cationic nature (Table 3.2). However, using this assembly method for R8-PLPs, we were
able to achieve CLP-equivalent siRNA loading without reaching elevated CLP-equivalent surface
charges. Previous studies using similar EtOH injection techniques have demonstrated enhanced
encapsulation of siRNA (~80%) with non-PEGylated liposomes comprised of DOPC and
cholesterol as bulk lipid constituents. However, the addition of PEG into the lipid formulation
drastically reduced siRNA encapsulation.70 Our results confirm the ability to enhance molecular
drug loading in PEGylated liposomes via the utilization of STR-R8. This is a significant finding
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considering PEGylation would be required to avoid premature clearance in future in vivo
applications using lipid nanoparticles.
The immunogenicity and cytotoxicity associated with cationic liposomes has prevented in
vivo translation for CLP formulations frequently described in the RNAi literature. These effects
could be attributed to both their cationic nature and the presence of synthetic lipid constituents
in their formulations.110 Though the addition of STR-R8 in the assembly of our CPP modified
neutral liposome showed modest increases in overall surface charge, all PLP and R8-PLP groups
were shown to be significantly less cytotoxic than CLPs (Fig. 3.4). In fact, most neutral liposomes
exhibited no cytotoxic effect at all, with cell death rates being equal to that of baseline.
Furthermore, consistent with R8’s enhanced translocation properties demonstrated in previous
gene transfer studies, even low levels of STR-R8 addition (>2.5mol%) enhanced cellular
association of neutral liposomes in our study (Fig 3.5).69,125,126

Specifically, R8-PLP-10mol%

dramatically enhanced cell association of non-modified-PLPs, though not to a level comparable to
tested CLP formulation. However, while there was no R8-PLP-10mol% effect on cytotoxicity,
CLPs were almost 2-fold more toxic than baseline.

Synthetic lipid constituents typically

comprising cationic liposomes, such as DOTAP in our CLP formulation, are responsible for
imparting their positive charge characteristics. However, once endocytosed, these unnatural
lipids cannot be efficiently degraded by the cell, thus promoting unfavorable interaction with other
cellular components.127 Alternatively, because STR-R8 is comprised of natural amino acids, and
all neutral PLP groups were composed of native lipid constituents, these liposomal nanoparticles
can be more efficiently degraded by the cell upon delivery, thus foregoing the cytotoxic effects
commonly seen in CLP-mediated transfection
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The negligible cytotoxicity, concurrent with

enhanced cellular association, exhibited by R8-PLPs here has revealed this class of CPP-modified
PLPs as an ideal candidate for in vitro and future in vivo applications.
Due to the ideal cytotoxicity and cellular association profiles demonstrated here, R8-PLP10mol% was empirically identified as an optimal R8-PLP for further investigation in its efficacy as
a molecular nanocarrier for liposomal-mediated RNAi in VSMCs. Based on our previous studies
with polymeric bioconjugates, suggesting differential cargo carrying capacities across nanoparticle
materials, we tested variations in lipid-to-siRNA w:w ratios as a means of delineating the optimal
carrying capacity of our R8-PLP-10mol% liposomal formulation.

For this proof-of-concept

analysis, GAPDH was targeted as our gene of interest due to its abundant expression, ease of
knockdown evaluation, and our groups previously established protocols to demonstrate chemical
and polymeric transfection efficacy of VSMCs in vitro using siGAPDH screening.106,107 Here w:w
was adjusted between 2.5-20:1 using R8-PLP-10mol% and tested alongside PLP and CLP groups
to compare gene silencing efficiency using qPCR analysis of GAPDH expression. We were able
to demonstrate significant silencing at both 10:1 and 20:1 w:w R8-PLP-10mol% when compared
to non-treated controls, while silencing with non-modified PLP and CLPs was not significant.
While the requirement for CPP modification of PLPs in order to achieve significant silencing was
an expected result, the lack of CLP effectiveness was an interesting finding. This may be explained
by reduced cytosolic uptake and increased lysosomal degradation imposed by the addition of PEG
molecules to the CLP surface. The PEG shell around the exterior of the liposome nanoparticle
is roughly 5nm in thickness and completely surrounds the CLP surface, reducing the interaction
between the cationic lipid head group of DOTAP and the endosomal membrane, thereby
effectively eliminating endosomal fusion and escape. In the case of STR-R8 it would appear that
the extension of R8 peptide into the PEG shell allows for a more favorable interaction for
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endosomal escape into the cytosol required for the siRNA-mediated gene silencing.124,128-130 To
account for any non-specific effects on baseline gene expression that may result from exposure
to nanoparticle constituents alone, comparative analysis was also performed against cells
transfected with NC siRNA under identical exposure conditions. Significant silencing efficiency
was further confirmed, eliminating the possibility for off-target effects of the lipid constituents
playing a role in gene regulation including possibilities such as mRNA half-life regulation, cellular
metabolism regulation, etc. Interestingly, w:w analysis demonstrated a high lipid requirement for
effective siRNA delivery. This suggests the need to form nanoparticles with a low liposomal
carrying capacity for efficient drug delivery (i.e. concentrated liposomes carrying reduced siRNA
cargo per liposomal carrier). This information can be important for the future development of
efficient transfection protocols to test molecular targets of IH-associated genes for in vitro
phenotypic analyses. But more importantly, defining an appropriate nanoparticle carrying capacity
range will be imperative for translation to in vivo models where lipid load and biodistribution
studies will be paramount in determining efficacy.
Further modifications for optimizing R8-PLP mediated transfection are still warranted, as
the level of silencing achieved in this study, using our liposomal carriers of interest, was lower
than levels that could be considered efficacious. This may be attributable to steric hindrance
provided via the PEG “shield”.131 The thickness of the linear PEG shell surrounding the liposome
surface (at ~5nm) is still about twice the length of the R8 peptide. It is plausible the PEG chain is
partially shielding the R8 peptide and thereby preventing its full cell penetrating properties.
However, maintaining the PEGylated properties of our drug delivery platform moving forward
will be paramount. The translation of liposomes to in vivo animal models has been extensively
studied, with results showing that grafting PEG to the surface is essential to reduce opsonization,
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improve stability, and increase half-life when administered in the vasculature.132 Therefore, our
future studies could investigate alternative avenues for the addition of R8 utilizing this PEG moiety
as a backbone for assembly, such as post-insertion or post-conjugation to the outer edge of PEG
using cyclooctyne as the clickable PEG moiety against azido-equipped peptides via copper-free
click chemistry techniques.133
In conclusion, we have established PLPs containing 10mol% STR-R8 as an optimal
transfection agent with minimal cytotoxicity and enhanced transfection capacity as compared to
CLPs in VSMCs. This nanoparticle could prove to be an optimal molecular nanocarrier in the
application of vascular gene therapeutics. More in vitro studies are needed to further develop this
lipid-based nanoparticle for application in translational medicine, but continued development of
this liposome delivery system could provide an avenue to a therapeutic treatment in the
pathological development of IH in a surgical model.
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CHAPTER 4: The Assembly of Ligand-modified PEGylated
Liposomes for Cell-type Selectivity in Vascular Cell Types
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The following chapter will be submitted for publication in a peer-reviewed manuscript format at
a future date.

4.1 Introduction
The utilization of surgery bypass grafting has gradually declined due to the advancements
of minimally invasive endovascular procedures such as percutaneous transluminal angioplasty
(PTA) and stent implantation. Unfortunately, intimal hyperplasia (IH) is a common adverse
response to PTA with or without stenting that can lead to restenosis and further revascularization
procedures with higher mortality and morbidity rates. Endothelial denudation is an avoidable
injury event during PTA revascularization procedures that exposes the underlying subendothelial
matrix and vascular smooth muscle cells (VSMCs) to hemodynamic flow. The endothelium, along
with producing vasoactive compounds and providing an impermeable barrier to the underlying
medial layer, has been shown to preserve the quiescent state of VSMCs through the local
production of nitric oxide (NO).134 For this reason, reendothelialization is considered a necessary
cellular event for long-term inhibition of neointimal formation after vascular injury. In fact, a
recent study demonstrated that VSMCs only appear in intimal layer areas lacking vascular
endothelial cell (VEC) recovery seven days after injury.135
Despite recent studies suggesting a focus on reendothelialization as therapeutic strategy
for IH-induced restenosis, the dysfunctional migration and proliferation of VSMCs has been
traditionally labeled as the key target of pharmacological interventions aimed at reducing
restenotic development in a surgical setting. Accordingly, most therapeutic interventions for IHinduced restenosis are aimed at attenuating the proliferative response of VSMCs at the site of
the treated lesion. For example, the use of antimitotic agents, like paclitaxel and sirolimus, have
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been successfully deployed in drug-eluting stents to reduce acute intimal thickening.136 However,
chronic restenosis still occurs in up to 60% of patients at 12-month follow-up angiography
primarily due to the concomitant inhibition of VEC recovery inherent in anti-proliferative
strategies. To increase therapeutic efficacy of current medical interventions in the reduction of
IH-induced restenosis, a cell-specific therapeutic strategy that inhibits the proliferative response
of VSMCs while promoting VEC recovery is required.
Liposomes are highly biocompatible drug delivery systems (DDS) that can be surface
decorated with ligands for a variety of downstream applications, including the directed cellspecific interaction within diseased tissues. This so-called “active targeting” through cell-targeting
peptide (CTP) modification has emerged as a valuable strategy to enhance liposomal DDS
properties and improved therapeutic index. The short peptide fragments REDV and VAPG have
recently been show to selectively bind vascular VECs and VSMCs, respectively.137 We have
postulated that these vascular cell-specific ligands, when conjugated to a noncationic PEGylated
liposome (PLP) surface, could impart a nanotechnology capable of delivering pharmacological
cargo in a cell-specific manner. Here we aim to establish the cell selective potential of VECspecific (EC-PLP) and VSMC-specific (SMC-PLP) PLPs through the surface conjugation of REDV
and VAPG, respectively. This approach could provide the ability to simultaneously deliver a
multitude of gene therapeutics or established pharmaceutics aimed at the simultaneous reduction
of VSMC migration and proliferation while simultaneously promoting VEC recovery.
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4.2 Materials and Methods
4.2.1 PLP Assembly via Ethanol Injection Technique
Liposome Constituents
All liposome formulation constituents are defined in Table 4.1. Lipids and cholesterol were
purchased from Avanti Polar Lipids (Alabaster, AL, USA). In accordance with previous literature
establishing cell-specific capacity of REDV and VAPG peptide fragments, respectively, a glycine
spacer was used for the REDV peptide and a valine-glycine dual amino acid spacer was used for
the VAPG peptide. The custom REDV peptide was purchased with an azido-modified lysine from
P3 Biosystems (Louisville, KY, USA). The custom VAPG peptide was purchased with an azidomodified lysine from P3 Biosystems (Louisville, KY, USA).
Liposome Assembly
Base PLP nanoparticles were formed with bulk lipid DOPC:chol at 7:3mol plus 10mol% DSPEPEG, and were assembled using a previously described EtOH injection technique. Briefly, lipids
were dissolved in CHCl3, combined as indicated, and dried under N2 gas and vacuum to remove
remaining solvent. Dried lipids were then resuspended in molecular grade 100% EtOH. 300uL
10mM Tris-HCl at pH 8.0 with 0-50mM CaCl2 was injected with 1000-2000 ug total lipid/200uL
in 100% EtOH, under constant vortexing at room temperature (RT). EtOH and un-encapsulated
siRNA was removed from liposomes via 24hr dialysis against PBS, pH 7.4 at 4 °C. Liposomes
were extruded using 100nm polycarbonate NanoSizerTM extruders from T&T Scientific prior to
characterization (Knoxville, TN, USA).
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Table 4.1: Liposome formulation constituents and associated acronyms.

Liposome Formulation Components
Lipid Constituent

Acronym

1,2-dioleoyl-sn-glycero-3-phosphocholine
cholesterol
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[dibenzocyclooctyl(polyethylene glycol)-2000]
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl)
VAPG-conjugated to DSPE-PEG

DOPC
chol
DSPE-PEG
DSPE-PEGdbco
Rho-PE
VAPG-PEG
REDV-PEG
SMC-PLP
EC-PLP
CTP-PLP

REDV-conjugated to DSPE-PEG
SMC-targeted PLP
EC-targeted PLP
Cell-targeting peptide-conjugated PLP

4.2.2 CTP-PLP assembly via VAPG and REDV Amphiphile Incorporation
REDV-PEG and VAPG-PEG Synthesis
DSPE-PEGdbco, a form of DSPE-PEG with a cyclooctyne modification commonly used in azidealkyne cycloaddition reactions (i.e. click chemistry), was used to form REDV-PEG and VAPG-PEG
amphiphiles for PLP incorporation. Briefly, equimolar azido-modified REDV and VAPG peptides
were combined with DSPE-PEGdbco at RT under constant agitation for 2hr, according to
previously established reaction conditions.71,72
PLP Modification with REDV-PEG or VAPG-PEG
For all modification strategies, base PLPs were assembled via EtOH injection as described, and
were modified by substituting DSPE-PEG with REDV-PEG or VAPG-PEG amphiphiles at equal
mol%, respectively. In this way mol% PEG was kept constant across all conditions to control
PEG-induced changes in cell association while comparing cell associative contributions from
REDV or VAPG, respectively.
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Modification via Pre-insertion
REDV-PEG or VAPG-PEG were combined at 1-5mol% with base PLP lipid constituents at the
time of lipid drying under N2 gas. Likewise, lipid hydration with EtOH was performed in onestep and all lipid constituents were incorporated at the time of initial liposome assembly.
Liposomes were purified from un-encapsulated siRNA as described, prior to extrusion and
characterization.
Modification via Post-insertion
Base PLPs were assembled as described without the incorporation of R8 amphiphiles. Following
PLP purification by dialysis, R8-PEG or STR-R8 were combined with pre-formed base PLPs and
incubated at 4°C overnight or 37°C for 4 hours, according to previously established conditions
for lipid transfer. A second overnight dialysis was performed following R8-amphiphile insertion
to remove any un-retained siRNA encapsulate, prior to extrusion and characterization.
4.2.3 Liposome Characterization Studies
Size, Homogeneity, and Charge Characterization
The mean size, associated polydispersity index (PDI), and zeta potential of all liposome
preparations were measured by dynamic light scattering and relative electrophoretic mobility in
water using the Zetasizer Nano ZS instrument (Malvern Instruments Ltd., Worchestershire, UK).
Morphological Characterization by Scanning Transmission Electron Microscopy
Liposome morphology and lamellarity were investigated by STEM using a negative-stain method.
Liposomes were applied dropwise to a carbon film coated copper grid and allowed to air dry.
Liposome films were then stained with 2% phosphotungstic acid and air-dried for 1min at room
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temp. Samples were visualized with Zeiss Auriga 40 STEM scope, and images were acquired by
SmartSEM image acquisition software (Carl Zeiss, Inc., Oberkochen, Germany).
4.2.4 Vascular Cell Culture
Human aortic smooth muscle cells (HASMCs) and Human aortic endothelial cells
(HAECs) were obtained from LifeLine Cell Technology (Walkersville, MD). Cells were incubated
at 37°C in an environment of 5% CO2 and 95% humidity and grown in VascuLife growth medium
(VascuLife Basal Medium + VascuLife smooth muscle cell supplement kit OR Vasculife endothelial
growth supplement kit + gentamyocin/amphotericin; LifeLine Cell Technology).
4.2.5 Cell Association Experiments
To measure cell association, liposomes were assembled as described with the addition of
Rho-PE at 0.5mol%. VSMCs were treated with Rhodamine-labeled neutral PLPs and CTP-PLP
groups at 100uM total lipid in DMEM at >80% confluency. After 1hr, 4hrs and 24hr liposome
exposure, cells were washed three times in PBS and qualitatively imaged by fluorescent
microscopy. Images were acquired with a Texas Red fluorescent filter at 400X under 400msec
exposure across all groups. For quantitative analysis, cells were washed three times in PBS, lysed
with 1% Triton X-100, and centrifuged at 12,000 RPM for 5min at 4°C to remove cell debris.
Cell lysates (100ul) were plated in duplicate in 96-well plates, and cell association of rhodaminelabeled liposomes was determined by fluorimetry at 575nm. Cell association was determined by
mean arbitrary fluorescence units (AFU) of each sample, minus baseline fluorescence of nontreated controls receiving no Rhodamine source within each experimental replicate.
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4.2.6 Statistical Analysis
All data are reported as mean ± SEM. Statistical analyses were performed using Student’s
t-test or one-way ANOVA and a post-hoc Student-Newman-Keuls test using SPSS 25 software
(Systat Software, Inc., San Jose, CA). Probability (P) values ≤0.05 were considered to be significant.
4.3 Results
4.3.1 The Incorporation of CTP Does Not Significantly Affect Size or Homogeneity
of CTP-PLPs Compared to PLP Controls.
The incorporation of VAPG-PEG via pre-insertion or post-insertion does not
significantly affect the nanoparticle size or PDI of assembled SMC-PLPs compared to PLP
controls (Fig 4.1 and 4.2). Likewise, the incorporation of REDV-PEG does not significantly
affect size or PDI of assembles VEC-PLPs compared to PLP controls (Fig 4.3 and 4.4).
4.3.2 The Incorporation of VAPG-PEG into PLP Base Formulations Results in
Desired Morphological Characteristics.
TEM images of SMC-PLPs modified with 5 mol % VAPG-PEG confirms size of <100nm in
diameter, spherical morphology, and unilamellarity (Fig 4.5). Quantitative measurements made
using SmartSEM image acquisition software showed a diameter of 71.35 nm and 73.86 nm,
respectively. From this we can see that all liposomal nanoparticles shown in image fall within
size distribution exhibited by DLS data.
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Figure 4.1: Comparison of average size (d.nm) as a result of VAPG incorporation into PLPs using pre-insertion and
post-insertion techniques.
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Figure 4.2: Comparison of polydispersity index (PDI) as a result of VAPG incorporation into PLPs using preinsertion and post-insertion techniques.

Figure 4.3: Comparison of average size (d.nm) as a result of REDV incorporation into PLPs using pre-insertion
technique.

96

Figure 4.4: Comparison of average size (d.nm) as a result of REDV incorporation into PLPs using pre-insertion
technique.

Figure 4.5: STEM images of SMC-PLPs modified with 5 mol % VAPG. This image confirms that the assembly
process preserves liposomal morphology and unilamellarity, and confirms quantitative size measurements made with
DLS.
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4.3.3

The Incorporation of VAPG-PEG into SMC-PLPs Increases Cell Association

Above PLP Controls in VSMC but Not VEC.
The incorporation of 0.5, 1.0, 2.5, and 5.0mol% VAPG-PEG via pre-insertion achieved
2.31±0.73, 2.45±0.65, 3.02±0.73, and *3.42±0.77-fold increase in cell association in VSMC and
1.17±0.18, 1.23±0.18, 1.75±0.39, and 2.01±0.59-fold increase in cell association in VEC,
respectively, after 4 hour treatment (*P<0.05 vs. PLP in SMC; n=5, Fig. 4.6).
4.3.4 The Incorporation of VAPG-PEG into SMC-PLPs via Post-insertion Does Not
Significantly Increase Cell Association in SMCs Compared to PLP Controls.
The incorporation of 0.5, 1.0, 2.5, and 5.0mol% VAPG-PEG via post-insertion achieved
1.93±0.80, 2.11±0.65, 1.86±0.66, and 1.96±0.43-fold increase in cell association in VSMC and
1.57±0.36, 2.26±0.47, 2.03±0.54, and 2.32±0.44-fold increase in cell association in VEC,
respectively, after 4 hour treatment (Fig. 4.7).
4.3.5 The Incorporation of REDV-PEG into EC-PLPs Increases Cell Association
Above PLP Controls in VEC but Not VSMC at Early Exposure.
The incorporation of 0.5, 1.0, 2.5, and 5.0mol% REDV-PEG via pre-insertion achieved
0.95±0.17, 1.32±0.15, 1.10±0.12, and 1.09±0.28-fold change in cell association in VSMC and
1.11±0.07, *1.59±0.01, 1.38±0.16, and 1.35±0.30-fold change in cell association in VEC,
respectively, after 1 hour treatment (*P<0.05 vs. PLP in VEC; n=3, Fig. 4.8).
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Figure 4.6: The relative cell association of VAPG modified CTP-PLPs compared in HASMCs and HAECs. PLP
controls and SMC-PLPs were assembled as described with the addition of Rho-DOPE at 0.5mol%, and cell association
was determined by mean arbitrary fluorescence units (AFU) of each sample, minus baseline fluorescence of nontreated controls receiving no Rho-DOPE. *P<0.05 vs. PLP in VSMC; n=5; NS vs. PLP in VEC.
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Figure 4.7: The relative cell association of VAPG modified CTP-PLPs using post-insertion technique compared in
VSMCs and VECs. PLP controls and SMC-PLPs were assembled as described with the addition of Rho-DOPE at
0.5mol%, and cell association was determined by mean arbitrary fluorescence units (AFU) of each sample, minus
baseline fluorescence of non-treated controls receiving no Rho-DOPE.
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Figure 4.8: The relative cell association of REDV modified CTP-PLPs using pre-insertion compared in VSMCs and
VECs after 1 hour treatment. PLP controls and EC-PLPs were assembled as described with the addition of RhoDOPE at 0.5mol%, and cell association was determined by mean arbitrary fluorescence units (AFU) of each sample,
minus baseline fluorescence of non-treated controls receiving no Rho-DOPE. *P<0.05 vs. PLP in VEC; n=3
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4.3.6 The Incorporation of REDV-PEG into EC-PLPs Does Not Significantly Increase
Cell Association Above PLP Controls at Later Time Points.
The incorporation of 0.5, 1.0, 2.5, and 5.0mol% REDV-PEG via pre-insertion achieved
0.83±0.11, 1.16±0.10, 1.19±0.18, and 1.04±0.10-fold change in cell association in VSMC and
0.78±0.19, 1.19±0.18, 1.08±0.04, and 0.91±0.02-fold change in cell association in VEC,
respectively, after 4 hour treatment (Fig 4.9).
4.4 Discussion
Therapeutic strategies using ligand-modified CTP-PLPs for cell-specific targeting have been
studied in wide variety of disease targets, including atherosclerotic lesions and vascular injury.
Targeted nanomedicine is a promising approach in treating vascular injury in a surgical model due
to the contradictory outcomes produced by current therapeutic paradigms.138 Most therapeutic
modalities are geared towards the inhibition of VSMC contribution to neointima formation.
Unfortunately, these anti-proliferative therapies also prohibit the effective healing of the intimal
layer comprised of VECs. We propose that an optimal pharmacological strategy would provide
a therapeutic application that discretely inhibits VSMC migration and proliferation, while also
promoting VEC recovery.
The extracellular matrix (ECM) helps delineate where specific cell types reside within
tissues based on cell selectivity with common ECM components. For this reason drug discovery
and proteomics studies have revealed “cell-selective” peptides based on their interaction with
the ECM. VAPG (val-ala-pro-glycine) and REDV (arg-glu-asp-val) have been chosen as the SMCspecific and EC-specific ligand candidates in this study due to their small size and simplicity. VAPG,
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Figure 4.9: The relative cell association of REDV modified CTP-PLPs sing pre-insertion compared in VSMCs and
VECs after 4 hour treatment. PLP controls and EC-PLPs were assembled as described with the addition of RhoDOPE at 0.5mol%, and cell association was determined by mean arbitrary fluorescence units (AFU) of each sample,
minus baseline fluorescence of non-treated controls receiving no Rho-DOPE. *P<0.05 vs. PLP in VEC; n=3
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an elastin-derived ECM binding sequence, and REDV, a fibronectin-derived ECM binding
sequence, were shown to have VSMC and VEC specific attachment under shear flow
conditions.139 The previously established cell-specific fragments, VAPG and REDV, were attached
to PLP surfaces via azide-alkyne click chemistry techniques, exposing them on the edge of the
PEG scaffold.
First, we examined the effect of VAPG-PEG and REDV-PEG incorporation on PLP
characterization.

We looked at size, PDI, liposome morphology, and lamellarity.

The

incorporation of VAPG-PEG and REDV-PEG into PLPs showed no significant difference in size or
PDI when compared to unmodified PLP. STEM images confirm that VAPG modified liposomes
display a spherical morphology, consistent with liposomal assembly. The measured sizes using
STEM imaging are less than 100 nm in diameter and fall within the range of measured average size
using DLS. Also, these liposomes are unilamellar in nature, a characteristic required for functional
gene delivery.
Next, we investigated the VSMC-specific cell association of SMC-PLPs modified with
VAPG-PEG. VSMCs and VECs were given 4 hour treatments with SMC-PLPs containing 0.5, 1.0,
2.5, and 5mol %, respectively, due to previously optimized cell association of PLPs in VSMCs (data
not shown). The addition of 5 mol % VAPG-PEG to PLP enhanced cell association ~3.5-fold in
VSMCs when normalized to PLP controls with no VAPG. On the other hand, no significant
enhancement of cell association was shown in VECs using this SMC-PLP formulation.
Additionally, there was no significant difference between VSMC-related and VEC-related cell
association within VAPG groups.

This would indicate that, even though VSMC-specific

association was shown by SMC-PLPs when compared to PLP control, the cell-specific affinity is
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diminished due to the fact that there is some increase in cell associative potential in VECs. The
addition of VAPG-PEG via post-insertion did not convey any enhanced cell association in VSMCs
when normalized to PLP. This would indicate that post-insertion of VAPG-PEG is inefficient.
Chemical and physical studies utilizing high performance liquid chromatography (HPLC) in line
with evaporative light scattering detection (ELSD) to measure relative abundance of ligandconjugated lipids would be required in the future. Regardless, these assays confirm that VAPGdecorated PLPs confer some VSMC-specific potential.
Similarly, we conjugated REDV to the surface of PLPs to produce EC-PLPs. Interestingly,
when treated for 4 hours with EC-PLP, there was no significant enhancement of cell association
in VSMCs or VECs. However, when we shortened this treatment time to 1 hour, the addition
of 1mol % REDV-PEG was shown to significantly enhance cell association in VECs ~1.59-fold.
There was no observed increase in VSMCs for EC-PLPs when normalized to PLP.
The lack of cell-specific differences observed within each group for both SMC-PLP and
EC-PLP treatment in vitro would suggest that these “targeted” liposomes are inadequate for in
vivo translation. This could be due to the presence of the PEG shell in PLP formulations, which
can inhibit short peptides from interacting with cell surface even if exposed on surface. Also,
these experiments were performed in static cell culture conditions, unlike previous studies where
cell-specificity of VAPG and REDV were established under flow conditions. Future studies
utilizing a flow chamber for cell culture may be required to elucidate cell-specific attachment.
Our ultimate goal was to establish cell-specific potential of SMC-PLPs and EC-PLPs
modified with VAPG and REDV, respectively. Although both peptides conferred cell-specific
affinity when compared to PLP controls, further investigation is necessary before in vivo
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administration is warranted. It may be necessary to use folded peptides or monoclonal antibodies
with recognized affinity to create the cell-specific affinity necessary for translational studies. In
conclusion, we have established a proof-of-concept technique whereby our previously established
ethanol injection assembly method and resulting noncationic PLP vector can be modified via click
chemistry techniques to confer cell-targeting capabilities.
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CHAPTER 5: Conclusions and Future Directions
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5.1 Study Conclusions and Future Directions
Technological advancements in medicine have revolutionized how surgeons treat
occlusive disorders of the vasculature. Endovascular surgery is a minimally invasive technique
that provides surgeons with a low-risk treatment option for PVD patients to restore adequate
blood flow at the site of atherosclerotic lesions. Unfortunately, these procedures inherently
induce endothelial damage, which triggers adverse remodeling of the vessel, otherwise known as
IH. IH can lead to restenosis and subsequent revascularization procedures with higher costs and
morbidity. Gene therapy has the potential to mitigate restenosis by targeting specific gene targets
previously implicated in IH development. Although there is a large volume of optimistic basic
science research in the field of gene therapy, the primary hurdle to translational and clinical
success is the delivery system. A nanocarrier system with favorable pharmacokinetic properties
and minimal toxicity and immunogenicity is required to realize bench-to-bedside success of gene
therapeutics.
As an in vitro proof-of-concept study, this dissertation project aimed to accomplish the
following main objectives:
1) Develop a noncationic PLP with reduced cytotoxicity, improved loading efficiency, and
enhanced transfection capacity compared to traditional LDS for siRNA delivery.
2) Develop a cell-type specific PLP equipped with SMC-specific and EC-specific functional
motifs to differentially target vascular cell types for siRNA delivery.
The research herein provides a novel LDS platform for siRNA delivery with a high degree of
translational potential.

Through continuous optimization and process improvement, this
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liposomal siRNA nanotechnology could provide a foundation leading to improved clinical success
of gene therapy in vascular disease and other disease pathologies.
In chapter 2, we demonstrated a novel assembly technique that produces PEGylated
liposomes with CQAs required for the effective delivery of gene therapeutics in a downstream
translational model. Specifically, the research herein shows that the addition of STR-R8 into PLPs
utilizing the pre-insertion technique is a simple and efficient method to produce noncationic CPPmodified liposomes with enhanced cell association and optimal siRNA loading efficiency. The
siRNA encapsulate is stable within the CPP-PLP nanocarrier, which provides nearly complete
protection from nuclease digestion in the external environment. This technique provided a
foundational procedure to assemble noncationic liposomal siRNA delivery systems for in vitro
investigation in vascular cell types.
In chapter 3, we established neutral, CPP-modified liposomes as efficient nanocarriers in
VSMCs. We confirmed that incorporating 10mol% STR-R8 in PLP formulations provides an
optimal transfection agent with minimal cytotoxicity and enhanced transfection capacity as
compared to cationic liposomes. The cytotoxicity associated with common cationic vectors like
CLPs and PEI has plagued the gene therapy field for decades, and is the primary reason LDS fail
en route to clinical approval. The ability of these nanocarriers to employ functional siRNAmediated gene knockdown with minimal cytotoxicity is crucial to the downstream success of
noncationic platforms in liposomal siRNA delivery.
Chapter 4 is a proof-of-concept study that demonstrates the ligand-mediated, discriminate
targeting of noncationic PLPs to VSMCs and VECs, respectively. Modification of PLP base
formulations with VAPG-PEG and REDV-PEG enhanced cell association above PLP controls in
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respective vascular cell targets. Although we achieved discrete enhancement above unmodified
PLP controls with both SMC-specific and EC-specific liposomes, the addition of VAPG and REDV
did not significantly improve cell-selective association within ligand-modified groups. The level of
cell-selectivity would need to be clear and palpable for effective cell-targeted delivery in vivo,
therefore further optimization is required.
We will continue to expand development of cell-selective liposomal platform in future
studies using customary modification strategies established in LDS literature.

Monoclonal

antibodies provide much higher affinity for their respective cell targets than small peptide
fragments like VAPG and REDV. The incorporation of antibodies to PLP surfaces to convey celltype specific delivery has been successfully demonstrated in vitro and in vivo. Although the surface
chemistry and orientation of large molecules introduces greater complexity to the PLP assembly
process, we aim to incorporate monoclonal antibodies and antibody fragments onto the PLP
surface to provide cell-type specific capabilities to our previously established noncationic siRNAloaded PLPs. Also, the use of pre-insertion technique, while simplistic and scalable, can produce
inefficient assemblies where the ligand is internalized and rendered useless. We intend to
investigate the use water-in-oil emulsification techniques for tightly controlled surface-decoration
of functional ligands in noncationic PLPs.
We are committed to continuous in vitro, ex vivo, and in vivo validation of our noncationic
liposomal siRNA platform in hopes of establishing a gene therapeutic aimed at attenuating IH
development in a surgical model. Likewise, the simple, scalable assembly technique, established
in Chapters 2 and 3, provides a springboard for the development of other LDS modalities for
improved drug delivery and effective RNAi therapy in vascular disease and beyond. As assembly
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parameters and surface chemistry techniques continue to be optimized by our group novel LDS
modalities for clinical application will continue to be developed with ancillary projects. This
includes the development of spatially-controlled liposomes, cell-mimetic liposomes, and
theranostic liposomes.
For example, our group recently aimed to tailor PLP lipid formulations to mimic
membranes of vascular cell types. For instance, the addition of phosphatidyl serine (PS) and diacyl
glycerol (DAG) adds lipid complexity to our unilamellar liposome system commonly seen in cells,
which could augment liposomal drug delivery. These specific lipids are highly involved in lipid
signaling and vesicular trafficking within the cell, which could plausibly promote cellular uptake of
noncationic PLPs. Utilizing the assembly method herein, a recently published study from our
group demonstrates that the use of DAG and PS could enhance therapeutic potential of our R8PLP via enhanced cell associative properties.140
Also, our group is interested in the spatial control of siRNA-loaded PLPs within the
vasculature. Recently, we demonstrated successful localization and collagen-specific affinity of
ligand-conjugated liposomes. A novel peptide with specific affinity for human collagen Type IV
was chosen as a ligand candidate for future studies. In a study recently submitted for peer-review
publication, our group established that, by decorating PLP surface with collagen-binding peptides,
ligand-conjugated liposomes demonstrated increased binding affinity to collagen matrices under
flow conditions. The idea is that, by targeting exposed subendothelial collagen in vascular injuries,
liposomes can be directed to vascular lesions for downstream therapeutic and diagnostic
applications.
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The purpose of this dissertation was to establish a noncationic PLP capable of augmented
transfection potential, enhanced siRNA encapsulation, reduced cytotoxicity, and cell selectivity
in vascular cell types, while meeting all CQAs required for effective systemic administration of
liposomal nanomedicine. Our research has elucidated a simple and efficient method for producing
noncationic R8-modified liposomes with enhanced cell association and siRNA loading efficiency.
We have confirmed that these novel liposomal nanocarriers containing STR-R8 amphiphiles are
effective transfection agents in VSMC with minimal cytotoxicity compared to traditional CLPs. In
addition, PLPs produced using this novel assembly method can be further modified to convey cellspecific properties in VSMC and VEC alike. The novel LDS developed in this study will provide
the foundation for future pre-clinical in vivo validation studies using our previously established
animal model of vascular injury and IH development in rat carotid arteries. However, further in
vitro development is required to move towards an animal model and increase translational
potential in a clinical setting. We have proposed that the development of a targeted liposomal
vector capable of discrete delivery of therapeutic genes to VSMCs and VECs, respectively, could
provide an optimal pharmacological approach to prevent IH-induced restenosis in response to
vascular injury. The novel siRNA-loaded PLP developed herein will provide the foundation for
future clinical applications of gene therapy aimed at preventing IH-induced restenosis.
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